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Abstract 
Type 2 diabetes has reached epidemic proportions worldwide. The resulting increase in chronic 
and costly diabetes related complications has potentially catastrophic implications for healthcare 
systems, and economics and societies as a whole. One of the key pathological factors leading to 
type 2 diabetes is insulin resistance (IR), which is the reduced or impaired ability of the body to 
make use of available insulin to maintain safe glucose concentrations in the bloodstream. 
It is essential to understand the physiology of glucose and insulin when investigating the 
underlying factors contributing to chronic diseases such as diabetes and cardiovascular disease. 
For many years, clinicians and researchers have been working to develop and use model-based 
methods to increase understanding and aid therapeutic decision support. However, the majority 
of practicable tests cannot yield more than basic metrics that allow only a threshold-based 
assessment of the underlying disorder. 
This thesis gives an overview on several dynamic model-based methodologies with different 
clinical applications in assessing glycaemia via measuring effects of treatment or medication on 
insulin sensitivity. Other tests are clinically focused, designed to screen populations and diagnose 
or detect the risk of developing diabetes. Thus, it is very important to observe sensitivity metrics 
in various clinical and research settings. 
Interstitial insulin kinetics and their influence on model-based insulin sensitivity observation was 
analysed using data from the clinical pilot study of the dynamic insulin sensitivity and secretion 
(DISST) test and the glucose-insulin PK-PD models. From these inputs, a model of interstitial 
insulin dose-response that best links insulin action in plasma to response in blood glucose levels 
was developed. The critical parameters influencing interstitial insulin pharmacokinetics (PKs) 
are saturation in insulin receptor binding (αG) and the plasma-interstitium diffusion rate (nI). 
Population values for these parameters are found to be [αG, nI]=[0.05,0.055]. 
Critically ill patients are regularly fed via constant enteral (EN) nutrition infusions. The impact 
of incretin effects on endogenous insulin secretion in this cohort remains unclear. It is 
xiii 
 
hypothesised that the identified SI would decrease during interruptions of EN and would increase 
when EN is resumed, where, for short periods around transition, the true patient SI would be 
assumed constant. The model-based analysis was able to elucidate incretin effects by tracking the 
identified model-based insulin sensitivity (SI) in a cohort of critically ill patients. Thus, changes 
in model-based SI given the fixed assumed endogenous secretion by the model would support the 
presence of an EN-related incretin effect in the population of non-diabetic, critically ill patients 
studied. 
The PD feedback-control model of Uen was designed to investigate endogenous insulin secretion 
amongst subjects with different metabolic states and levels of insulin resistance. The underlying 
effects that influence insulin secretion i.e. incretin effects were also defined by tracking the 
control model gain/response and the identified insulin sensitivity (SI) using intravenous (IV) 
bolus and oral glucose responses of insulin sensitivity tests. This new PD control model allowed 
the characterisation of both static (basal) and dynamic insulin responses, which defined the 
pancreatic β-cell glucose sensitivity parameters. However, incretin effects were unobserved 
during oral glucose responses as the PD control gains failed to simulate the true endogenous 
insulin secretion due to potentially inaccurate glucose appearance rates and low data resolution 
of glucose concentrations. 
The net effect of haemodialysis (HD) treatment on glycaemic regulation and insulin sensitivity in 
a critically ill cohort was investigated. It was hypothesized that the observed SI would decrease 
during HD due to enhanced insulin clearance compared to the model, and would be recaptured 
again when HD is stopped. The changes in model-based SI metric at HD transitions in a cohort of 
critically ill patients were evaluated. Significant changes of -29% in model-based SI was 
observed during HD therapy. However, there were insignificant changes when HD treatment was 
ended. Thus, the changes in model-based SI would thus offer a unique observation on insulin 
kinetics and action in this population of critically ill patients with ARF that would better inform 
metabolic care.   
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Chapter 1. Introduction  
The number of people with diabetes has significantly increased in recent years to approximately 
350 million people worldwide (Chen et al. 2011). Chronic hyperglycaemia is the main 
characteristic of diabetes and is directly associated with morbidity and mortality (Capes et al. 
2000; Krinsley 2003; Krinsley 2004; Van den Berghe et al. 2001). In 2004, an estimated 3.4 
million people died due to hyperglycaemia (ADA 2006a). Thus, it is suggested that diabetes has 
reached epidemic proportions, with catastrophic implications on quality of life, healthcare costs 
and population as a whole (Bonow and Gheorghiade 2004; Chiu et al. 2001; King 1999).  
The general symptoms of diabetes can be alleviated with glycaemia control protocols in 
intensive care unit (ICU), which are reported to reduce the risk of other metabolic complications 
i.e. cardiovascular, sepsis, acute renal failure, and etc. (Chase et al. 2008; Evans et al. 2011; 
Krinsley 2004; Van den Berghe et al. 2001). Also, understanding the underlying metabolic 
disorders that contribute to the pathogenesis of diabetes can potentially prevent the risk of 
developing this disease at the very early stage or provide the best approach to treat diabetes 
before it becomes chronic. This chapter discusses the overall prevalence, its development and 
underlying causes of diabetes. Review on its current clinical diagnosis assessment methods and 
glycaemic control protocols for critically ill patients are also presented. 
1.1 Pathogenesis Type II Diabetes Mellitus (T2DM)  
The pathogenesis of T2DM is a more gradual process than type 1 diabetes. It generally starts 
with the pre-diabetes stages of impaired glucose tolerance (IGT) and impaired fasting glucose 
(IFG), before a clinical classification of diabetes can be made. The progression of this disease is 
often undiagnosed and untreated for many years, until first health complications start to appear. 
The physical symptoms that usually occurred in T2DM are listed as follows: 
 Dehydration and frequent urination. As blood glucose concentration builds up in the 
bloodstream, fluid is absorbed from the tissues which cause dehydration. Thus, it 
increased the fluid consumption and urinates more frequently than normal. 
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 Increased appetite. Without enough insulin to bind with cells in peripheral tissues and 
muscles causes‘ energy depletion that triggers intense appetite. 
 Weight loss. The body uses alternative fuels stored in muscle and fat as source of energy 
due to decreased glucose metabolism in the bloodstream.  
 Fatigue. The body becomes tired and exhausted as the cells are deprived of glucose. 
 Blurred vision. This symptom only occurs when hyperglycaemia causes excessive fluid 
appearance in the eyes lenses. 
 Low immunity system. T2DM affects the body‘s ability to heal and resist infections. 
Later, it may cause sepsis if it is untreated. 
 
Typically, T2DM is not recognised early enough to intervene before permanent damage has 
begun to occur, and is thus often diagnosed only when treating its symptoms or complications at 
later levels (Gastaldelli et al. 2004; Kleinfield 2006). This late diagnosis is due to the nature of 
the disease development, where noticeable symptoms do not arise until significant irreversible 
damage has occurred. With accurate early diagnosis pre-diabetic states could potentially 
identified up to 3-5 years earlier (Andersson et al. 2009; Clark et al. 2000; Pannala et al. 2009) 
which can significantly reduce the onset of further damage and complications. 
T2DM is increasingly diagnosed among children, adolescents and younger adults (Hossain et al. 
2007).  The causes of this epidemic disease are embedded in a very complex group of genetic 
besides the integrated between quality of life and environmental influences. Given that both 
insulin secretion and its kinetic are under genetic control, failure of β-cell function and/or IR 
could theoretically be the primary factors in T2DM (DeFronzo and Ferrannini 1991; Kahn 2003; 
Poulton et al. 2002; Staiger et al. 2009; Stumvoll et al. 2005). This common aspect presumably 
reflects the development of IR at the peripheral and receptor level, particularly in the liver, 
skeletal muscle and heart (Andrews and Walker 1999; Reaven 1988; Shulman 2000).  
The chronological treatment of T2DM consists first of lifestyle changes to increase insulin 
sensitivity. Increases in exercise with healthier diet and weight loss are proven to increase insulin 
sensitivity and thus reduce the prevalence or impact of T2DM (Duncan et al. 2003; McAuley et 
al. 2002; Nishida et al. 2004; Tuomilehto et al. 2001). This is may be combined with medication, 
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such as thiazolidinedionesn (Rosiglitazone), biguanides (Metformin) or sulfonylureas 
(Glyburdie) to enhance insulin sensitivity or stimulate the pancreas secretion (Kahn et al. 2006). 
Lastly, insulin replacement therapy (i.e. exogenous insulin input via insulin pump) as in type 1 
diabetes, is required to maintain glucose homeostasis (Hermansen et al. 2002; Pickup and Keen 
2002; Schaumberg et al. 2005; Steil et al. 2006) 
1.2 Development of model-based SI test 
The model-based insulin sensitivity methods have shown significant ability to diagnose and 
characterise pre-diabetic state (Beard et al. 1986; Bergman et al. 1987; Boston et al. 2003; Chase 
et al. 2008; Lotz 2007; Mari et al. 2001a; McAuley et al. 2011; Pacini and Bergman 1986; 
Wallace and Matthews 2002). Model-based approaches measure the physiological effects that 
explain the causes to progression of diabetes. Model-based SI tests typically use empirical 
methods, mostly regression models that are designed to correlate well with certain gold standard 
test metrics i.e. euglycaemic/hyperglycaemic clamp (EIC) (Beard et al. 1986; Bergman et al. 
1987; DeFronzo et al. 1979; Mari et al. 2001a; Pacini and Bergman 1986). 
If fasting metrics are used insulin sensitivity is only quantified during a fasting state which may 
be different to postprandial sensitivity. It is also assumed that the insulin secretion from β-cells 
can be measured by sampling C-peptide concentrations (Pacini and Mari 2003).  The elevated 
insulin concentrations can cause endogenous glucose production inhibition (EGP). The level of 
inhibition can be measured with the additional use of glucose tracers (Caumo and Cobelli 1993). 
Thus, SI metrics can be different to the real-observed during the dynamic or hyperglycaemic state 
used in other applications (Scheen et al. 1994) as the total SI is defined as the total amount of 
insulin sensitivity at peripheral cells and liver.  
It is important to model all the kinetic behaviour of insulin and glucose including: insulin 
clearance, endogenous glucose production, endogenous insulin secretion and to segregate the 
dynamics (i.e. incretin effects) to fully describe the important aspects of the true metabolic 
system. Figure 1.1 shows an overview of the physiological effects that can be measured by SI 
tests. However, these effects can only be captured by the model depending on the design and 
application of the tests.  
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Figure 1.1 Overview of the physiological effects measured by insulin sensitivity tests. Depending on the 
design of the test, it can measure either one, a combined effect if two, or all three of these effects. The 
dashed lines indicate a mediated or enhanced effect. 
The main effects contributing to insulin dependent glucose uptake (in Figure 1.1) which reflect 
the insulin sensitivity are the sensitivity of tissue cells to bind insulin (peripheral sensitivity), the 
effect of insulin on the liver to secrete glucose production (hepatic sensitivity), and the ability of 
the pancreas to produce insulin with increase in glucose concentration (β-cell function). These 
effects are time varying and are different in fasting or perturbed states (Scheen et al. 1994). 
Depending on the structural design of the chosen method to assess SI and its assumptions, one or 
more of these effects can be combined in the assessment. Thus, different clinical and 
physiological interpretations can be delivered depending on varying results obtained from the 
chosen approach. 
1.3 Model-based glycaemic control protocol  
It is reported that model-based glycaemic control (GC) protocols ensure a reduction in 
hypoglycaemia in the ICU (Chase et al. 2007; Chase et al. 2008; Evans et al. 2011; Hovorka et 
al. 2007; Le Compte et al. 2009). The motivation of these protocols is to reduce clinical burden 
in ICU and also lessen the chronic outcomes due to organ failure, which increased morbidity and 
thus mortality. Model-based control relies on a physiological model that captures the glucose-
GLP-1/GIP 
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insulin system dynamics that accurately predict blood glucose, given specific insulin and glucose 
inputs. A control algorithm can use these predictions to select optimal insulin and nutrition 
interventions for forthcoming periods. 
The potential of models for managing glycaemic levels in critically ill patient is thus becoming 
realised. However, few models have been clinically validated. For most models, the primary 
form of validation has been simple fitting of the model to match clinical data (Carson and 
Cobelli 2001). Occasionally, more rigorous prediction validation, which tests the models ability 
to predict the outcome of a known intervention on retrospective clinical data (or in a clinical 
trial) is used. However, only a few clinically validated models can predict within clinically 
acceptable ranges (Chassin et al. 2004; Lotz et al. 2008; Pielmeier et al. 2010; Plank et al. 2006; 
Wong et al. 2006).  
Despite its clinical uses, glycaemic control (GC) in ICU also introduced secondary benefits. 
Studies by Weekers et al. (2003) and Langouche et al. (2005) indicate that glycaemic control 
reduces glucotoxicity due to high blood glucose, which in turn reduces oxidative stress and 
superoxides, which are stress hormone responses that cause damage to the endothelium and 
vascular walls.  
Simple model-based GC protocols have been successfully developed and piloted (Chase et al. 
2008; Chee et al. 2002; Evans et al. 2011; Fisk et al. 2012; Plank et al. 2006; Shaw et al. 2006). 
These model-based methods are able to identify evolving patient-specific parameters and tailor 
therapy appropriately. The principal of model-based control uses a physiological model that 
relies on a single, time-varying parameter, in this case SI, to capture the patient-specific 
glycaemic response to insulin. As an identified parameter, SI is prone to capturing other 
dynamics and metabolic effects which can be used to quantify metabolic dysfunctions and 
variability in critically ill patients. Although maintaining safe, effective model-based glycaemic 
control in critically ill patients has proven difficult, due to considerable inter- and intra- patient 
variability, it may offer the most practical, robust, adaptive and patient-specific solution to 
manage this issue. Success is thus a function of the model‘s ability to accurately capture the 
dynamics of insulin kinetic over time in the highly variable critically ill patient. 
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1.4 Preface 
The objective of this thesis is to understand and validate various pharmacokinetic and 
pharmacodynamic (PK-PD) models in wider research and clinical settings and present analyses 
of several important insulin kinetic and metabolic dysfunctions which affect the model-based 
insulin sensitivity.  
This thesis focuses on the kinetic parameters of the (PK-PD) models that affect the insulin 
secretion, insulin transport kinetics, incretins, and insulin clearance. Additionally, the impact of 
haemodialysis treatment in critically ill patients and the renal insulin clearance and insulin 
secretion were also presented. A brief overview of the thesis includes:   
Chapter 2 presents the physiology of plasma insulin, glucose, C-peptide and incretins.  
Chapter 3 reviews current model-based SI assessments used in research and clinical settings and 
its applications. 
Chapter 4 investigates the modelling of interstitial insulin actions, using different clinical-
validated PK and PD models with DISST data.  
Chapter 5 quantify and analyses the incretin effects of critically ill patients that underwent the 
SPRINT protocol.  
Chapter 6 develops a control model for pancreatic insulin secretion as a function of glucose 
excursions. 
Chapter 7 assesses the impact of haemodialysis (HD) therapy on insulin kinetics and action in 
critically ill patients with acute renal failure. 
Chapter 8 and 9 summaries the key aspects of the thesis and present possible future applications 
for this research. 
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Chapter 2. Physiology of Plasma Insulin, Glucose, C-peptide   and 
Incretins 
This chapter describes the physiology and biochemical characteristics of insulin, glucose, C-
peptide and incretin. These effects are captured in dynamic models that seek to segregate the 
dynamic effects of insulin sensitivity, insulin secretion and other metabolic effects. Hence, it 
provides foundation of the necessary basic knowledge needed to create effective, realistic 
models. 
2.1 Glucose 
Glucose (C6H12O6) is a monosaccharide used as the main source of energy in the body. It is 
oxidised in the cells to generate adenosine triphosphate (ATP) molecules which in turn provides 
energy to the cell (Guyton and Hall 2000). Glucose is transported around the body passively in 
the bloodstream. It also can be diffusively without insulin taken up by cells in the brain and the 
central nervous system, as they are highly permeable to glucose. However, muscle, adipose 
tissue cells and intestinal cells contribute to a majority of the total uptake. If available in 
abundance, glucose is stored by the liver and peripheral cells as glycogen for future use (Guyton 
and Hall 2000; Zierler 1999). Most of the body‘s cells require the hormone insulin to mediate 
glucose uptake (Despopoulos and Silbernagl 2003; Guyton and Hall 2000). Thus, insulin acts as 
a biochemical signal that unlocks cellular pathways of cellular glucose uptake, rather than as an 
integral part of that uptake. Hence, this uptake is referred to as insulin-mediated. 
Glycogenesis is the process of storing excess circulating glucose as glycogen in the liver. If 
glycogen stores are saturated, glucose is converted into fat and stored in the liver and in fat cells 
in the adipose tissue. These processes can be reversed when the energy demand is high. Glucose 
is rapidly released from glycogen via the glycogenolysis process if glycogen stores are used, 
once fat is used via the gluconeogenesis process with amino acids to form glucose (Guyton and 
Hall 2000; Zierler 1999). 
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Both glycogenolysis and gluconeogenesis are commonly grouped under and described as 
endogenous glucose production (EGP) (Zierler 1999). EGP is tightly regulated in the healthy 
body to maintain basal (minimum) blood glucose concentration. EGP represents net glucose 
produce by the body, primarily by the liver, and released into the blood (Cherrington 1999). EGP 
is suppressed when blood glucose concentration is considerably high due to external glucose 
appearance through meals or to a lesser extent via intravenous bolus (Caumo and Cobelli 1993; 
Jefferson et al. 2001; Pretty 2012). However, low glucose concentrations inverse the process by 
stimulating glucagon secretion via pancreatic α-cells, which activates glycogenolysis and thus 
rapidly increases glucose concentrations to prevent hypoglycaemia. 
The rate of endogenous glucose production is a function of both stimulus and availability of 
substrates. In reality, EGP is modulated by the interaction of many hormones in response to 
metabolic dysfunctions that cause insulin sensitivity irregularities (Gelfand et al. 1984; Mizock 
2001). As tissue cells fail to respond adequately to insulin, blood glucose concentrations rise. 
Normally, the liver helps regulate glucose concentrations by reducing glucose production in the 
presence of insulin. However, this may not occur in T2DM due to insulin resistance that reduced 
glycogen synthesis and storage and a failure to suppress glucose production. In critical illness, 
this lack of suppression of EGP is enhanced (Capes et al. 2000; McCowen et al. 2001; Thorell et 
al. 2004). 
The body naturally regulates blood glucose levels as a part of metabolic homeostasis. It is 
suggested that healthy fasting blood glucose concentration ranges between 4.4-5.1 mmol.L
-1
 (80-
92 mg.dL
-1
). Prolonged malnutrition or exposure to insulin can result in mild hypoglycaemia 
(low blood glucose <4.0 mmol.L
-1
 or 72 mg.dL
-1
). Severe hypoglycaemia (<2.2 mmol.L
-1
 or 40 
mg.dL
-1
) can limit the availability of energy to the brain and nervous system that can cause un-
consciousness or death. Alternatively, hyperglycaemia is also dangerous and occurs when blood 
glucose is elevated above safe levels (>11.1 mmol.L
-1
 or 200 mg.dL
-1
) with mild hyperglycaemia 
is defined as BG>7.0 mmol.L
-1
 (125 mg.dL
-1
). A subject with a fasting blood glucose range 
between 5.6 and 7 mmol.L
-1
 can be diagnosed with impaired glucose tolerance (IGT), while >7 
mmol.L
-1
 (125 mg.dL
-1
) can diagnose type 2 diabetes. Prolonged hyperglycaemia is highly toxic 
to a wide range of tissues and can result in diabetic retinopathy leading to partial blindness; and 
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decay of peripheral capillaries which may finally require body parts be amputated. Importantly, a 
continuous glucose homeostasis to normal levels is essential for positive on-going health 
benefits, and is equally true for hyperglycaemic critically ill patients. 
2.2 Plasma Insulin 
Insulin is a hormone secreted by the pancreas within the β-cells of the islets of Langerhans. 
Within the islets of Langerhans, β-cells constitute 65-80% of all the cells. Insulin has a leading 
role in maintaining glucose homeostasis. It enables glucose uptake by muscle and adipose tissue 
cells, regulates storage and release of glucose in the liver and promotes fat synthesis and storage 
(Guyton and Hall 2000; Jefferson et al. 2001). The pancreas secretes plasma insulin into the 
portal vein, where it first passes through the liver and subsequently enters systemic circulation. 
Glucose uptake is activated once plasma insulin is distributed to interstitial fluid, where it binds 
to cell-membrane receptors (Jefferson et al. 2001) as shown in Figure 2.1 
Insulin secretion by the pancreas is bi-phasic in healthy subjects (Guyton and Hall 2000; 
Jefferson et al. 2001; Prager et al. 1986; Sherwin et al. 1974). The first phase is a release of 
stored insulin in response to significant changes in glucose concentration. The magnitude of the 
first phase insulin secretion is typically to the rate of changes in glucose and the glucose gradient 
between the periphery and the portal vein (Cherrington 1999).  
The second phase is a prolonged, slow release of newly formed insulin dependent on glucose 
concentration. When the first phase insulin secretion is diminished, blood glucose concentrations 
will increase significantly right after oral ingestion. The pancreas compensates for this rise by 
increasing the second phase insulin secretion, which eventually brings blood glucose 
concentrations back to normal. However, these high levels of glucose and insulin in the 
bloodstream may damage the β-cells and further impair their ability to function. As a result, 
hyperglycaemia and T2DM occur in conjunction with hyperinsulinemia as a result of increased 
insulin resistance. 
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This response to glucose can be broadly modeled using a proportional-derivative (PD) feedback 
controller. This approach has been used to attempt closed loop control of diabetes and for tight 
glycaemic control (TGC) for critically ill patients (Chase et al. 2006; Chee et al. 2003; Steil et al. 
2006). Its popularity in representing insulin secretion is the basis for its use in glycaemic 
controllers. 
 
Figure 2.1 Schematic of insulin binding to receptors on tissue cells to activate glucose uptake. (Figure 
taken from medicinexplained.blogspot.co.nz). 
Circulating insulin is mainly cleared through by the liver, accounting for up to 60% of total 
insulin clearance (Duckworth et al. 1988; Ferrannini and Cobelli 1987; Sherwin et al. 1974). 
Approximately 30-60% of endogenous insulin is extracted by the liver in the first pass after it is 
released into the portal vein (Duckworth et al. 1988; Ferrannini and Cobelli 1987; Prager et al. 
1986; Sherwin et al. 1974; Toffolo et al. 2006). This mechanism allows a fast response and 
control insulin circulation and kinetics. Insulin is also cleared by the kidney (Duckworth et al. 
1998; Mak 1995; Rabkin et al. 1984) and through cellular degradation after binding to allow 
glucose uptake in the periphery (Guyton and Hall 2000; Jefferson et al. 2001). Insulin has two 
different half-lifes at 4-6 minutes and 20-30 minutes (Duckworth et al. 1998; Turnheim and 
Waldhausl 1988). 
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Plasma insulin concentrations control cellular glucose uptake, which consequently affects blood 
glucose levels. When glucose concentrations are high insulin suppresses the hepatic release of 
stored glucose (EGP). Insulin also causes hepatic glucose storage through promotion of glycogen 
synthesis (via glycogenesis) as glucose concentration increases. In summary, insulin is essential 
in controlling and maintaining glucose levels and homeostasis. 
2.3 Plasma C-peptide 
Like insulin, C-peptide (connecting peptide) is produced by the β-cells located in the islets of 
Langerhans in the pancreas (Despopoulos and Silbernagl 2003; Guyton and Hall 2000). C-
peptide is distinguished as a by-product of insulin secretion, as both peptides originate from the 
precursor Proinsulin, which then splits into insulin and C-peptide, as shown in Figure 2.2. Thus, 
both species are secreted in equimolar amounts (Rubenstein et al. 1969). The main difference is 
that C-peptide is only cleared by the kidney, so it is very stable in use to estimate endogenous 
insulin secretion (Van Cauter et al. 1992).    
 
Figure 2.2 Proinsulin chain is joint by two chains of insulin and C-peptide. The precursor proinsulin is 
cleaved internally at two sides (arrows) to yield insulin and C-peptide. (Figure taken from medical-
dictionary.thefreedictionary.com/insulin). 
Historically, C-peptide was assumed to be a waste product of insulin secretion (Wahren 2004). 
However, a recent study has indicated a biologically active role, in binding to cell membranes 
and activating intra-cellular signalling pathways, resulting in improved renal and nerve functions 
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(Luppi et al. 2011). These identified effects are not critical for this research and generally do not 
affect the modelling approach as its function does not affect its appearance or degradation. 
It is suggested that C-peptide is only cleared by the kidney and it thus has a longer single half-
life (~2-5 times longer) than plasma insulin (Rubenstein et al. 1969). Thus C-peptide has higher 
concentrations than insulin in the peripheral circulation and less fluctuation in its concentration 
compared to insulin. These effects allow uncomplicated measurement and models to capture the 
kinetics of C-peptide, and thus endogenous insulin secretion. 
In particular, plasma C-peptide concentrations reveal the pancreatic insulin secretion due to the 
equimolar secretion of the hormones. In fact, the slower and less variable clearance by a single 
pathway (rather than three) makes C-peptide modelling more reliable for estimating endogenous 
insulin secretion rather than using insulin concentration itself. As a result, the models that 
illustrate C-peptide compartments are independently linking between C-peptide kinetics and 
insulin kinetics (Eaton et al. 1980; Faber et al. 1979; Hovorka et al. 1996; Lotz 2007; McAuley 
et al. 2011; Polonsky et al. 1986; Van Cauter et al. 1992). 
2.4 Incretins 
Incretin effects are defined as insulin responses triggered by a group of gastrointestinal hormones 
that enhance insulin secretion from the β-cells of the pancreas after glucose ingestion 
(Creutzfeldt and Ebert 1985; Nauck et al. 1986). Incretin hormones cause glucose to produce a 
greater insulin response than intravenous glucose infusions for the same content of glucose 
(Polonsky et al. 1988). They thus enhance insulin secretion responses. There are two recognised 
main incretin hormones: glucagon-like peptide 1 (GLP-1) and glucose-dependent insulinotropic 
polypeptide (GIP). These hormones are rapidly deactivated by the enzyme dipeptidyl peptidase-4 
(DPP-4) as illustrated in Figure 2.3. 
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Figure 2.3 Schematic of the incretin effects by meal ingestion (Phillips and Prins, 2012).  
Prior experiments show that up to 60% of the insulin responses after oral glucose consumption 
are not caused by a direct mechanism of glucose with β-cells in the islets of Langerhans, but by 
the secretion and action of incretins (Nauck et al. 1986; Nauck et al. 1993). Initially, GIP was 
identified as the first incretin hormone based on the insulinotropic actions of intestinal mucosal 
extracts which had been depleted of GIP (Creutzfeldt and Ebert 1985). A continuing incretin 
effect was noticed when circulating GIP was inactivated by anti-GIP antibodies (Ebert et al. 
1983). This led to the discovery of additional incretin hormones, GLP-1. This peptide was found 
to be an insulinotropic agent that responsible for stimulating insulin secretion, especially at 
increased glucose concentrations (Kreymann et al. 1987; Nauck et al. 1993; Qualmann et al. 
1995). Both peptides are suspected to suppress glucagon secretion from the pancreas (even at 
basal levels) (Gromada et al. 1998; Schirra et al. 1996) and decelerate gastric emptying (Nauck 
et al. 1997; Ørskov et al. 1996) and acid secretion (Schjoldager et al. 1989), and thus achieve 
their effect on insulin secretion. 
2.5 Summary 
To define and quantify the kinetics of glucose and insulin, a physiological PK-PD model could 
be used. A physiologically accurate PK-PD model should include the main volumes of 
distribution, the main mechanisms of transport between compartments and the dominant 
irreversible clearance dynamics. In addition, physiologically-relevant PK-PD models should also 
capture the dynamic effects that in turn affect insulin sensitivity allowing researchers and 
GUT 
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clinicians to understand and investigate the underlying factor to treat diabetes and other 
metabolic dysfunctions.  
The physiology to be modelled includes:  
 The effectiveness of insulin in maintaining glucose homeostasis (via insulin sensitivity 
metrics) 
 Insulin secretion mechanism into the bloodstream from the pancreas  
 Insulin clearance by the liver (first-pass hepatic extraction) and kidney 
 Interstitial insulin kinetics which are defined by transcapillary transport into interstitial 
fluid, reaching tissue cells where it binds to activate glucose uptake 
 Finally, insulin degradation at the peripheral cells. 
 
The specific physiological effects to be investigated in this thesis: 
 Parameters of insulin kinetics that influence model-based insulin sensitivity in overall 
metabolic PK-PD models 
 The incretin effects that enhance insulin secretion 
 Effects of insulin secretion and insulin clearance during haemodialysis (HD) treatment, 
which affects clearance. 
 
Overall, it is essential to appreciate the physiology and interaction of glucose and insulin with 
other related mechanisms in investigating the underlying factors contributing to chronic diseases 
such as diabetes, cardiovascular disease and acute renal failure. For many years, clinicians and 
researchers have been working to develop and use model-based methods to increase 
understanding and aid decision support. The physiological foundation presented in this chapter is 
the basis of ensuring models are relevant. 
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Chapter 3. Model-Based Insulin Sensitivity Assessments 
Insulin resistance (IR) has been widely accepted as the leading risk in the pathogenesis of Type 2 
Diabetes Mellitus (T2DM) and cardiovascular disease (CVD) (DeFronzo and Ferrannini 1991). 
A long-term study has shown those who developed T2DM had an average initial IR 60% higher 
than those who remained healthy (Martin et al. 1992). An early diagnosis of this condition can 
reduce further complications through early intervention (ADA 2002; McAuley et al. 2002). 
Hence, simple and practical tests to identify insulin sensitivity would be clinically beneficial that 
enable researchers and clinicians to clearly understand and assess the underlying physiological 
and metabolic effects which caused these diseases. Such tests can be enabled by accurate, 
physiologically relevant metabolic models. 
3.1 Introduction 
Insulin sensitivity (SI) is a measure of the efficiency of plasma insulin in reducing blood glucose 
concentration. There are many available tests measure this effect that all use somewhat different 
approaches (Bergman et al. 1979; Breda et al. 2002; Caumo et al. 2000; DeFronzo et al. 1979; 
Ferrannini and Mari 1998; Lotz et al. 2010; Matsuda and DeFronzo 1999; Matthews et al. 1985; 
McAuley et al. 2011; Pacini and Bergman 1986; Pacini and Mari 2003). Thus, it is necessary for 
the researcher/clinician to decide which test is best for any given condition in terms of intensity, 
cost, accuracy and physiological relevance. This decision thus implicitly states that there exists a 
hierarchy of such tests, each with different clinical method, and associated level of accuracy or 
resolution. 
In addition, insulin sensitivity can be affected by lifestyle changes. Increases in exercise, 
healthier diet (Duncan et al. 2003; McAuley et al. 2002; Nishida et al. 2002; Tuomilehto et al. 
2001) and weight loss (Camastra et al. 2005; Ferrannini et al. 2005; Ferrannini et al. 1997) are 
proven to improve sensitivity and thus reduce the prevalence or impact of type 2 diabetes. 
Hence, insulin sensitivity is affected by subject condition and a range of external variables. 
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SI estimation has numerous uses in medical and clinical situations. However, high-resolution 
tests (i.e. EIC and hyperglycaemic clamp) that would be beneficial for clinical SI measurement 
and monitoring are too intensive, long and costly for regular use. In addition, the sensitivity 
metrics yielded by the tests can be derived using models of the glucose-insulin 
pharmacodynamics that require more complex mathematical processes to evaluate than simpler 
clinical metrics. A comprehensive understanding and modelling of the variability in insulin 
sensitivity can assist clinical glycaemic control or intervention and minimise the associated risk 
of hyperglycaemia and/or hypoglycaemia, and thus mortality in critically ill patients. Thus, 
numerous clinically verified dynamic protocols have been developed to deliver data that enable 
SI identification using various specific or generic glucose-insulin (PK-PD) models with 
mathematical methods and algorithms. 
This chapter gives an overview on several dynamic model-based methodologies with different 
clinical application in assessing SI. Such assessments are typically used mainly in research to 
assess the effects of treatment or medication on insulin sensitivity. Other tests are clinically 
focused, designed to screen populations and diagnose or detect the risk of developing diabetes. 
Thus, it is very important to observe sensitivity metrics (SI) in various clinical and research 
settings. 
3.2 Overview of current model-based SI assessments 
3.2.1 Euglycaemic clamp test (EIC) 
The euglycaemic-hyperinsulinaemic clamp (EIC) was first proposed by DeFronzo et al. (1979). 
The test‘s concept based on constant infusion rate of insulin, while glucose has a variable 
infusion rate in order to ―clamp‖ the plasma glucose concentration at a normal fasting plasma 
glucose concentration. The test is very flexible, as it can be performed at different target of 
glycaemic or insulinaemic concentrations to study changes in metabolic effects at these specific 
target states. It also can be combined with tracers or other drugs to assess the metabolic effect on 
glucose uptake. The test is considered as the gold standard method in assessing insulin sensitivity 
(Ferrannini and Mari 1998; Pacini and Mari 2003). In particular, the accuracy is good and it is 
highly repeatable (DeFronzo et al. 1979; Mari et al. 2001b; Monzillo and Hamdy 2003). 
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The EIC requires a cannula placed in the antecubital fossa to allow directly insulin and glucose 
infusions into bloodstream. A second cannula is placed in the dorsum of the hand for blood 
sampling. Heating of the hand surface is included in most study designs to maintain constant 
blood circulation, which reduces errors/noise in terms of measuring blood samples representative 
of overall, whole body concentrations. The surface of the hand is usually warmed using a 
purpose-built heated-hand-box, which heats and circulates air around the participant‘s hand. The 
temperature of the heated air is generally controlled between 40 and 70
o
C. 
The test begins when insulin is infused at a rate proportional to the participant‘s size. The rate of 
insulin infusion is defined to achieve target of certain plasma insulin concentration (typically ~ 
100 mU.L
-1
), where healthy fasting concentrations are only relatively 5 to 10 mU.L
-1
 and 50 to 
70 mU.L
-1
. This high concentration is supra-physiological and creates a hyperinsulinaemic that 
completely suppresses the hepatic glucose production and pancreatic insulin secretion. Thus, the 
glucose uptake rate is presumably equivalent the glucose infusion rate eliminating several 
variables. A glycaemic steady state needs to be achieved to use this assumption, which can take 
between 2-3 hours (Ader and Bergman 1987). 
A glucose infusion begins 2-5 minutes after the insulin infusion to maintain euglycaemia 
between 4 and 5 mmol.L
-1
. A closed loop system with glucose sampling every 10 minutes, and a 
continuous adjustment of the glucose infusion rate (DeFronzo et al. 1979; Ferrannini and Mari 
1998) is required to reach and hold this euglycaemic steady state (Bergman et al. 1985). 
Measured insulin sensitivity signifies mainly peripheral sensitivity, as endogenous glucose 
production (EGP) is inhibited. 
The EIC derived insulin sensitivity index (ISI) is defined as the mean glucose infusion at steady 
state, M, divided by the mean insulin concentration I at steady state: 
    
 
 
 3.1 
 
Based on above ISI, it is assumed that the infused glucose (M) is cleared by the average plasma 
insulin present over that hour. As a result, this ratio is physiologically relevant since EGP is 
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suppressed at very high insulin infusion rates while a steady state fasting glucose concentrations 
is well maintained. It thus minimises the variability due to EGP effect on the measured 
sensitivity index. 
Overall, these tests are highly repeatable with a reported CV=6-10% (DeFronzo et al. 1979; Mari 
et al. 2001a; Monzillo and Hamdy 2003). It also offers a steady state assessment of a wide range 
of possible metabolic conditions as the glucose concentration can be clamped at any reasonable 
value, typically around 4.6 mmol.l
-1
 e.g. (McAuley et al. 2001). Thus, the EIC is used in 
evaluating other SI tests‘ performance by correlated it to the clamp metric ISI.  
3.2.2 Intravenous Glucose Tolerance Test (IVGTT) 
Intravenous tests utilise an injection or infusion of glucose and/or insulin to cause a physiological 
perturbation of the metabolic system. Previous studies report that higher accuracy is generally 
achieved with intravenous (IV) tests compared to tests with oral dose stimulus due to the 
variability and difficulty in measuring the rate of glucose appearance after oral glucose ingestion 
(Breda et al. 2001; Caumo et al. 2000; Dalla Man et al. 2005b; Mari et al. 2001b). Thus, IV tests 
minimise modelling errors and variability in the resulting estimated SI. However, they are 
invasive and time consuming to perform individually. Hence, they are typically used only in 
research settings, as they are too expensive and intense for a wider clinical use. 
A simple model description of the glucose dynamics observed during an IVGTT protocol is 
illustrated in the minimal model (MM) presented by Bergman et al. (1979). Metabolic 
information on glucose kinetics and dynamics can be obtained by identifying the model 
parameters to match IVGTT data (Bergman et al. 1981; Pacini and Bergman 1986). The model 
differentiates between hepatic glucose balance (  
  ) and insulin-glucose mediated uptake, 
(  
  ). Insulin dependent glucose uptake is portrayed by a kinetic model of so-called ‗insulin 
action‘. The model captures a minimal description of physiological insulin secretion aspects. The 
MM was a very early approach used mathematical model for SI measuring. 
A typical IVGTT protocol includes cannula in the dorsum of the hand, and/or the antecubital 
fossa for blood samples and the application of an intravenous (IV) glucose input. A series of 
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blood samples are taken at 5-30 minutes resolution over 1.5 to 4 hours (depending on the 
protocol used) are taken to obtain the participant‘s basal condition (Bergman et al. 1981; Pacini 
and Bergman 1986). Then, a glucose bolus is given at t=0. The glucose bolus dose is typically 
dependent on the participant‘s weight or BSA (i.e. 0.3 g/kg body weight) to normalise this dose 
over a cohort. A further 4-50 samples are taken after the glucose bolus. Glucose and insulin 
samples were assayed to quantify SI using a variety of methods. SI is usually estimated using the 
non-linear least-squares parameter identification method with the MM proposed by Bergman et 
al. (1979). The Minimal Model (MM) is defined: 
 ̇     
  (    )     
  
  
 3.2 
 ̇         (    ) 3.3 
 
where Table 3.1 defines the variables. 
 
Insulin sensitivity is estimated as a function of identified values for p2 and p3: 
  
   
  
  
 3.4 
 
Table 3.1 Nomenclature of Equations 3.2-3.4. 
Parameter Description Unit 
G Plasma glucose concentration  mmol.L
-1 
Gb Basal plasma glucose concentration mmol.L
-1 
X ‗Action‘ of insulin i.e. insulin effect on net glucose decay mU.L-1 
Px Rate of intravenous glucose input mmol.min
-1 
  
       Decay of glucose concentration at basal insulin  min
-1 
p2 Total rate of insulin transport into the in-accessible compartment 
(interstitial) and efficiency of insulin into a single compartment 
min
-1 
p3 Total clearance of insulin from the in-accessible compartment  L.mU
-1
.min
-2 
VG Volume of glucose distribution  L 
I-Ib Plasma insulin concentration above basal mU.L
-1 
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There are several issues moted since the method was first validated (Bergman et al. 1987; 
Docherty et al. 2011; Donner et al. 1985; Finegood et al. 1984; Saad et al. 1994). The most 
significant issues are the over-parameterisation of the MM that causes the inability to segregate 
between insulin and non-insulin mediated glucose disposal and the resulting convergence to 
local, not global, error minima during the non-linear least-square identification process (Cobelli 
et al. 1998; Mari 1997; Pillonetto et al. 2002; Quon et al. 1994). The issue of over-
parameterisation can be somewhat mitigated by the application of complex Bayesian 
identification methods (Cobelli et al. 1999; Erichsen et al. 2004; Pillonetto et al. 2002). 
However, no complete solutions are available to remedy these issues that also significantly 
improve the diagnostic resolution and repeatability of these tests in clinical and research settings. 
Hence, MM methods are limited their ability to accurately capture SI. 
Both the   
   and   
   metrics are coefficients of functions of glucose concentration and 
quantify glucose disappearance over time. Thus, parameter value trade-offs can occur during the 
parameter identification process. As a result, intra-participant repeatability between tests is poor 
(Gelding et al. 1994; Monzillo and Hamdy 2003; Pillonetto et al. 2003; Quon et al. 1994). The 
net error increases further due to the discrepancy of clinical data to measure noise from assay 
error suspected from physiological mixing, ineffective cannula flushing or decay prior to assay. 
The IVGTT itself is ideal physiologically, as it includes the highly dynamic endogenous insulin 
secretion impulse response of the glucose-insulin PD system to a glucose bolus. When a glucose 
bolus is injected intravenously it triggers the bi-phasic endogenous insulin response (Ferrannini 
and Mari 2004). Thus, IVGTT delivers data from which both phases of β-cell function can be 
distinctively identified. Therefore, it also provides an opportunity to measure and assess 
pancreatic performance. However, further modifications to improve test performance need to be 
considered so that the MM is more physiologically relevant to the research studies (Callegari et 
al. 2003; Caumo and Cobelli 1993; Caumo et al. 1999; Ferrannini et al. 1988; Mari 1998), as the 
test becomes impractical for application in wider clinical settings (ADA 1998). 
Overall, as a result, several studies have shown an ambiguous correlation between   
   and the 
gold standard EIC (R=0.44-0.92) (Bergman et al. 1987; Finegood et al. 1984; Foley et al. 1985; 
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Galvin et al. 1992; Katz et al. 2000) with more results in the lower range. The outcome is 
dependent on the subgroups and cohorts studied, and potentially the specific protocols used. This 
wide range of correlation implies some question on the tests accuracy and/or robustness. The 
over-parameterisation issue using the MM and the limited accessibility to complex computer 
parameter identification algorithms have constrained the acceptance of the IVGTT for uses 
outside of clinical trials and research. Thus, caution must be practised in interpreting   
   and 
  
   values.    
3.2.3 Oral Glucose Tolerance Test (OGTT) 
The oral glucose tolerance test (OGTT) is clinically practical, easier for individual use and 
research relevant in investigating the incretin effects. Currently, various doses and sampling 
protocols are used either in research or clinical settings. However, a standard OGTT consists of 
ingestion of a 75-g or 50-g glucose drink, followed by blood samples (usually 0, 30, 60, 120, 
150, 180 minutes) for 1-3 hours (Pacini and Mari 2003). Blood glucose and plasma insulin 
concentrations, and sometimes C-peptide concentrations, are sampled. Due to its relative ease of 
administration, it is the current method of choice for a clinical diagnosis of diabetes as 
recommended by the American Diabetes Association (ADA 2006a). However, these assessments 
do not strictly measure a physiological effect, but only reflect the outcome of these effects. In 
turn, some studies have proposed mathematical models to measure and investigate the 
physiological effects using an OGTT data to directly assess SI. 
A series of model modifications have been suggested to apply the MM to OGTT responses. 
Thus, an initial study by Caumo et al. (2000) modified the MM to model glucose appearance in 
bloodstream have also been developed. Follow by other model-based methods for parameter 
estimation from OGTT data (Breda et al. 2001; Dalla Man et al. 2005a; Mari et al. 2005; Mari et 
al. 2001b). In practice, the dynamic and variable rate of glucose absorption from gut to the 
bloodstream is practically immeasurable and causes variability in results and computational 
parameter identifiability issues. In particular, the identified SI based on these proposed models is 
directly affected by this variable rate of glucose absorption. Thus, variations in absorption or 
appearance rates play a major confounding role in modelling the response to oral glucose-insulin 
stimulus. 
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Figure 3.1 illustrates schematic diagram of the minimal model used to interpret the insulin-
modified, Frequently Sampled Intravenous Glucose Tolerance Test, (FS-IVGTT), (Cobelli et al. 
1984; Saad et al. 1994) and the Meal Glucose Tolerance Test, (MGTT), or OGTT (Breda et al. 
2001; Caumo et al. 2000). The rate of glucose input to the model is from the impulsive dose of 
glucose (PX) for the insulin-modified FS-IVGTT. The MGTT/OGTT the rate of appearance of 
absorbed glucose (RABS) determines (PX) to the model. Other kinetic transport parameters are 
shown k1-5. 
Figure 3.1 Schematic diagram of the minimal model used to interpret the insulin-modified FS-IVGTT 
(Saad et al., 1994) and the MGTT/OGTT by Caumo et al. (2000).   
The challenge in using the MM in Equation 3.5 to analyse oral MGTT/OGTT data is to 
mathematically describe the rate of appearance of absorbed glucose reaches the systemic 
circulation as (PX) (as in Figure 3.1). Thus, Caumo et al. (2000) suggested a modification on 
glucose input rate of MM to anticipate the rate of oral glucose appearance in bloodstream in 
order to assess SI. 
The resulting mathematical expression in assessing OGTT derived SI is defined Caumo et al. 
2000: 
  (    )
   
       
         
       
             
       
 
3.5 
PX(t) 
OGTT / MGTT 
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where AUC denotes the area under the curve calculated from time zero to the end of the test. 
GE=p1V is the glucose effectiveness (mL.kg
-1
.min
-1
). Doral is the dose of ingested glucose per 
unit of body weight (mL.kg
-1
), and f is the fraction of ingested glucose that actually appears in 
the systemic circulation (i.e. survives gastrointestinal absorption and first-pass hepatic uptake). 
As individual estimates of GE and f are not available, these values are assumed from prior 
studies. GE=0.024 (dL.kg
-1
.min
-1
) (Best et al. 1996), and f=0.8 (Kolterman et al. 2003). 
This approach allows a direct measurement of IR during a more physiological state, and has been 
intensively used in considerable research and validation studies. Validation using a meal input 
against the insulin-modified FS-IVGTT was performed in healthy subjects with good 
correlations of R=0.89 (Caumo et al. 2000) and R=0.75 (Dalla Man et al. 2002). The OGTT 
version was validated against EIC, resulting in a correlation of R=0.81 (Dalla Man et al. 2005b) 
and yielded a moderate level of repeatability with CV=12-15% in a study by Breda et al. (2001).  
3.2.4 Dynamic Insulin Sensitivity and Secretion Test (DISST) 
The simple and low-cost test DISST is applicable in clinical and research settings and measures 
SI and insulin secretion. The DISST protocol uses a series of blood samples to measure the 
participants‘ response to administered glucose and insulin boluses. A simple version of DISST 
that measured 5 blood samples taken over a 35-minutes protocol uses low-dose, intravenous 
glucose (10-g) and insulin (1U) boluses as inputs. Thus, it is comparatively short and for less 
intense than the gold standard EIC protocol.  
The DISST model and identification method allow the intermittent sampling by fitting and 
refining physiological responses to the measured data (Lotz 2007; Lotz et al. 2010). The PK-PD 
of DISST model accounts for participant-specific losses of insulin to the hepatic and renal, 
saturation of insulin clearance at high concentrations, and diffusion and mass conservation of 
insulin between the plasma and the interstitial (Lotz et al. 2010). It is also possible to assess β-
cell function using established method from Van Cauter et al. (1992), using C-peptide assays. 
Thus, it provides SI and endogenous secretion, which no other test listed can do. 
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Participants had a cannula inserted into the antecubital fossa for blood sampling and bolus 
infusion. Blood samples were collected at t=0, 10, 15, 25, and 35 minutes as glucose, insulin and 
C-peptide concentrations were measured using these samples. A 10-g bolus of IV glucose was 
given at t=5 minutes and a 1 U Actrapid insulin bolus was given immediately after t=15-minute 
sample. After the test, all participants were required to remain at the clinic for 30 minutes and a 
small meal or snack was provided to them. 
The parameter identification methods of dynamic tests, such as the DISST, are sensitive to the 
timing of samples. Thus, the actual samples times are recorded for reference. The iterative 
integral method (IIM) or integral method is used to identify model-based SI, glucose distribution 
volume (Vg) and first-pass hepatic insulin extraction (xL) and subsequent hepatic insulin 
clearance (nL).  Metrics of β-cell function are derived from insulin secretion profiles that are 
deconvoluted from interpolated C-peptide measurements using the established method of Van 
Cauter et al. (1992).  
The DISST model defines the PK-PD of C-peptide, insulin, and glucose. The model relates the 
rate of glucose decay to the concentration of insulin available in the interstitium to provide a 
metric of insulin sensitivity. The model equations are defined: 
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where all variables and parameters are defined in Table 3.2. 
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Table 3.2 Nomenclature of the DISST model in Equations 3.6-3.10 
Parameter Description Unit 
C Plasma C-peptide concentration mU.L
-1 
Y Interstitial plasma C-peptide concentration mU.L
-1 
I Plasma insulin concentration mU.L
-1 
Q Interstitial plasma insulin concentration mU.L
-1 
G Glucose concentration mmol.L
-1 
k1, k2, k3 kinetic parameters min
-1 
Uen Rate of insulin secretion mU.min
-1 
Vp Distribution volume of insulin in the plasma L
-1 
nI Transition rate of insulin between plasma and interstitial L.min
-1 
nK Rate of  renal insulin clearance min
-1 
nL Rate of hepatic insulin clearance min
-1 
αI Saturation of hepatic insulin clearance L.mU
-1 
nC Rate of insulin clearance to cells min
-1 
Uex Bolus input of insulin mU 
xL Hepatic first-pass extraction of insulin 1 
pgu Glucose-dependent rate of glucose disposal min
-1 
P Glucose bolus mmol 
Vg Distribution volume of glucose L 
Gb Basal glucose concentration mmol.L
-1 
Qb Basal interstitial insulin concentration mU.L
-1 
 
First, the kinetic parameters of Equations 3.6-3.7 are quantified using functions of participant 
weight, height, gender, and age that were defined by Van Cauter et al. (1992). Then, a piecewise 
linear interpolation of the C-peptide data was used with these kinetic values in a deconvolution 
calculation to produce an endogenous insulin secretion profile. Finally, SI, Vg, nL, and xL (from 
Equations 3.8-3.10) were identified using the deconvoluted Uen profile, insulin and glucose 
measured data, and the iterative integral method (Hann et al. 2005; Lotz et al. 2010). The overall 
SI identification process from PK-PD of the DISST model is illustrated in Figure 3.2. 
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Figure 3.2 The overall method of estimating the model-based SI. Modeled peripheral insulin Q, and 
sampled glucose concentration data are combined in the glucose/insulin pharmacodynamic model. SI is 
estimated by fitting the model with the iterative integral method (IIM).  
A strong correlation between SI identified by the DISST and the glucose clamp as reported 
(R=0.82) by McAuley et al. (2011) with CV ranges of ~8-11% (Lotz 2007). Table 3.3 shows the 
DISST performances in comparison to the well-known HOMA metric for insulin sensitivity with 
correlation to the EIC. The HOMA result reported within the ranges in the literature (Bonora et 
al. 2000; Katsuki et al. 2001; Lotz et al. 2008; Mari et al. 2001b; Matthews et al. 1985; Pacini 
and Mari 2003). 
Table 3.3 Pearson correlations and c-ROC (area under the curve) values between the sensitivity metrics 
derived during the DISST study. 
 EIC 
R (c-ROC) 
DISST 0.82 (0.96) 
HOMA 0.60 (0.92) 
  
The DISST model and methodology is simple, requires minimal data to assess SI and is thus 
practically useful in both clinical and research settings. The test yields more information 
regarding glucose and insulin responses to stimuli than other available tests. It also compares 
well against other established and more intensive physiological approaches (Ferrannini and Mari 
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1998; Pacini and Mari 2003; Wallace and Matthews 2002). If the DISST were to be applied 
widely, it could potentially enhance over understanding of the pathophysiology of type 2 
diabetes and characterise subgroups among the heterogeneous cohort of IR individuals. 
3.2.5 Homeostasis Model Assessment (HOMA) 
HOMA is a computer-solved model that estimates insulin secretion and insulin sensitivity based 
on the interactions between fasting plasma glucose and insulin. The test index was derived from 
a physiological whole body glucose-insulin model, developed based on physiological data 
(Matthews et al. 1985). The same physiological model was also used in the assessment of 
CIGMA. Other test approaches measure SI in the presence of stimuli. However, HOMA only 
gives an estimate of basal insulin resistance. Caution should be used when making comparisons 
between studies due to variations in infusion protocols, sampling procedures and assay types 
used in different studies. 
The HOMA index is obtained from a simple equation of the fasting plasma glucose 
concentration (Gb) (mmol.L
-1
) and the fasting plasma insulin concentration (Ib) (mU.L
-1
), is 
defined:  
        
    
    
 3.11 
 
It is reported that the initial process in identifying IR index (or HOMA-SI) requires a series of 
samples measured on consecutive days (Wallace et al. 2004), which increases the clinical 
intensity. Due to its simplicity and comparability across studies, the HOMA measure is used in 
many research studies, as well as clinically. 
In addition, a separate HOMA index of β-cell function, HOMA-%B, can be estimated similar to 
Equation 3.12: 
        
    
      
 3.12 
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HOMA has been validated against the EIC. A wide spread of correlations values were obtained 
between a very poor R=0.22 and a very good R=0.93 (Bonora et al. 2000; Mari et al. 2001b; 
Mather et al. 2001; Matthews et al. 1985; Pacini and Mari 2003). In addition, average to poor 
CV values has also been reported between 10-20% (Bonora et al. 2000; Lotz et al. 2008; 
Matthews et al. 1985; Wallace et al. 2004). 
Currently, HOMA is used by clinical researchers, primarily to quickly and cheaply estimate IR. 
A relatively high CV and the lack of real-time measurements limit the tests diagnostic use. The 
HOMA metric assumes that SI will be inversely proportional to both insulin and glucose 
concentrations. However, the lack of test stimulus means that the effect of the pulsatile release of 
insulin (Del Prato et al. 2002; Meier et al. 2005) and assay error are significant and adverse 
confounding effects. In addition, the resolution of the HOMA metric is poorest in the region of 
maximum clinical utility. Thus, in many cases a simple fasting glucose is used instead, as it is a 
simple test and practical in a general clinical setting. 
3.2.6 Continuous Infusion Glucose Model Assessment (CIGMA) 
CIGMA is an intravenous test that consists of a relatively low dose infusion of glucose over 60 
minutes (5 mg.kg
-1
.min
-1
) to mimic a postprandial state. Sample of glucose and insulin were 
measured during the final 15 minutes which is approximately steady state (Hosker et al. 1985). 
Then, the test data are compared to known physiological data using a model of whole body 
glucose homeostasis (similar to Equation 3.11) that accounts for the glucose infusion rate and 
clearance. CIGMA has a reported repeatability of CV=17-21% (Hosker et al. 1985; Nijpels et al. 
1994) and reported correlations to the EIC vary between R=0.66-0.87 (Hosker et al. 1985; 
Nijpels et al. 1994). 
The estimated SI obtained is likely a good match to the true combined peripheral and hepatic 
sensitivity due to the physiological glycaemic state attained during the test. The test also is 
restricted and not applicable in individuals with a weak pancreatic insulin response or type 1 
diabetes (Ferrannini and Mari 1998). Thus, these limitations make it less useful and unreliable in 
clinical settings, although the relative simplicity, safety and potential physiological relevance 
make it appealing in research studies and some limited clinical situations. 
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3.3 Physiologic role of SI in model-based assessments and other uses 
Insulin sensitivity is not a discrete metric that can be assessed with a simple, well defined test. It 
is a concept to quantify the body‘s ability to reduce blood glucose concentrations in response to 
insulin secretion. This definition is very broad and includes many underlying physiological 
effects that contribute to the whole body response. Three major effects contribute to the overall 
whole body sensitivity and response to glucose, EGP, insulin sensitivity and β-cell function. 
Highly complex tests, such as EIC, IVGTT, and Oral Minimal Model assessment cannot 
differentiate between these three physiological effects without tracer labelled glucose and C-
peptide sampling. The DISST can segregate endogenous insulin secretion, which the others 
cannot. In turn, it is very difficult to compare such varied methods in assessing SI, as they also do 
not always measure the same physiologic effects. 
Insulin sensitivity in a fasting state can be significantly different (steady-state) than in the 
perturbed state (dynamic state) (Ferrannini and Mari 1998). In addition, SI can be different for a 
more physiological oral perturbation as oral glucose triggers insulin-stimulated gastrointestinal 
hormones (i.e. incretins) (McIntyre et al. 1965; Muscelli et al. 2008; Nauck et al. 1986; Vilsbøll 
and Holst 2004) that do not occur with IV glucose (Breda et al. 2001). It is essential to include 
all relevant physiological effects in the model assessment to portray the kinetics of glucose-
insulin and identify SI. Thus, SI can be evaluated in many different ways depending on clinical 
or/and research applications.   
One of the clinical roles of model-based SI is to capture the glucose-insulin metabolic system 
dynamics that accurately diagnose, monitor and predict blood glucose concentrations in 
glycaemic control of critically ill patients. Thus, a common aspect that portrays model success in 
modelling glucose/insulin pharmacodynamic-pharmacokinetic (PD-PK) is the model‘s ability to 
capture the glycaemic response to insulin, which is often expressed in terms of overall, whole-
body insulin sensitivity (Chase et al. 2008; Evans et al. 2011; Fisk et al. 2012; Hovorka et al. 
2007; Le Compte et al. 2009; Plank et al. 2006).  
It is suggested that IV tests have the highest repeatability, as the test protocols controls many 
variables. The highest repeatability reported is for the EIC due to the suppression of all 
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endogenous glucose and insulin secretion (reducing all the unknown dynamics). However, 
Cobelli et al. (1998) and Mari (1997) found that IVGTT triggers unmodeled regulatory responses 
that negatively affect model fitting. Thus, the potential remedy of these problems to improve the 
model accuracy is to modify the protocol, rather than creating complex modelling or clinical 
settings (Lotz et al. 2006). 
Oral-based SI assessments are more variable due to the variable appearance rate of glucose in 
bloodstream. The rate of gastric absorption is difficult to measure without tracers and can be very 
variable in different individuals. Thus, any estimation of this rate involves simplified 
assumptions contributes to a high variability in the overall test result. However, a larger number 
and heterogeneous of samples used in determining the SI metric can somewhat reduce variability 
by fully capturing the dynamic response without losing its functionality in screening T2D/IGT.  
3.4 Summary 
Overall, different studies have used different methods for assessing SI. However, it has been 
suggested (Groop et al. 1993) that the ideal method for measuring SI should satisfy five criteria:  
1. High insulin concentrations to stimulate glucose metabolism  
2. Observe the distinction between peripheral and hepatic insulin sensitivity 
3. Measure steady-state conditions 
4. Capture the physiologic glucose equilibrium system after IV/oral ingestion 
5. Reach a hyperglycaemic state which is not overtly non-physiological 
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Figure 3.3 Comparison of different SI assessments and target area for a better clinical test. The points are 
plotted according to the test‘s intensity and accuracy in terms of repeatability (CV in %). Intensity is a 
composite symbolic measure of cost, duration, and overall stress (labour) involved.  
Several different methods to measure SI have been proposed to date with varied complexity and 
accuracy as in Figure 3.3. Tests that quantify SI directly use intravenous or oral glucose 
administration and glucose, insulin and C-peptide measurements in order to capture the dynamic 
metabolic response to the perturbation. It can be concluded that the more repeatable tests such as 
EIC or IVGTT are only used in research settings, as they are too complex, clinically intense and 
costly for regular or widespread clinical use. 
A clinically useful test that is repeatable and provides a good resolution to monitor small changes 
in SI would assist an early and more accurate diagnosis of IR. Such a test could be engineered by 
considering the good aspects of available accurate research tests, while reducing their intensity 
and also minimising errors identified in their methods.  
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Chapter 4. Interstitial Insulin Action  
Delayed glucose uptake correlates closely with the changes in interstitial insulin rather than with 
plasma insulin, showing how interstitial insulin levels determine the uptake rate of glucose in the 
periphery (Castillo et al. 1994; Yang et al. 1994). From a model-based perspective, the critical 
parameters values that affect glucose uptake are transcapillary diffusion rate (nI) and insulin 
binding saturation (αG). These two parameters thus influence the identified patient-specific 
insulin sensitivity (SI).  This chapter uses glucose-insulin and C-peptide PK-PD models to 
analyse these parameters to determine a best set of parameter values. 
4.1 Introduction 
The DISST is a dynamic insulin sensitivity test using a low dose of insulin bolus with the 
addition of a low dose glucose bolus (Lotz 2007). Measurements are taken for blood glucose, 
plasma insulin and C-peptide. Insulin sensitivity, SI, and other patient-specific parameters are 
then calculated from a physiological model of C-peptide-insulin-glucose kinetics and dynamics. 
In a Monte Carlo study, the SI value from the DISST model achieves a correlation of R= 0.98 
(90%CI: [0.97, 0.98]) in SI to the ISI of the gold-standard euglycaemic clamp (EIC) when fit to 
clamp data (Lotz et al. 2008). In the DISST itself, the mean intra-patient variability between SI in 
different DISSTs is reported to be 11% compared to a value of 6% for the EIC (Lotz et al. 2010). 
Hence, the DISST and its identified SI metric accurately capture metabolic response.  
As measurements are only available for blood glucose, plasma insulin and C-peptide, many 
model parameters must be determined a-priori. This requirement limits the number of patient-
specific parameters to be identified, and thus improves the model identifiability (Docherty et al. 
2011). The kinetics of insulin and C-peptide have been extensively studied and are generally 
well understood (Duckworth et al. 1988; Duckworth and Kitabchi 1981; Van Cauter et al. 1992). 
However, interstitial insulin and pharmacokinetics of insulin receptors binding still present many 
unknowns (Duckworth et al. 1998). In particular, dysfunctions at the cellular level are largely 
speculated to contribute to insulin resistance (Barrett et al. 2009; Black et al. 1982; Brownlee 
and Hirsch 2006; Bryant et al. 2002; Duckworth et al. 1998). 
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Saturation in insulin-mediated glucose removal has been observed at varying levels (Docherty et 
al. 2010; Natali et al. 2000; Nestler et al. 1988; Prigeon et al. 1996; Rizza et al. 1981; Transberg 
et al. 1981). However, this effect is not taken into account by the EIC. Therefore, the EIC can 
underestimate insulin sensitivity as levels of plasma insulin are induced beyond physiological 
levels and beyond any linear relationship between glucose disposal and plasma insulin level 
(Docherty et al. 2011; Prigeon et al. 1996; Rizza et al. 1981). The model developed for the 
DISST also ignores insulin effect saturation, although the low insulin doses used were intended 
to avoid reaching saturation levels during DISST pilot study thus negotiating its need in that 
study (Lotz 2007) later uses of that model at higher doses have included insulin saturation (Lin et 
al. 2011). 
This chapter investigates interstitial insulin action and its influence on model-based insulin 
sensitivity. The analysis uses the data from the DISST clinical pilot study (Lotz 2007) and the 
Intensive Control Insulin-Nutrition-Glucose (ICING) model (Lin et al. 2011) and, from these 
inputs, develop a modeled interstitial insulin dose-response that best links insulin action in 
plasma to response in blood glucose levels. The critical parameters influencing interstitial insulin 
pharmacokinetics (PKs) are saturation in insulin receptor binding and the plasma-interstitium 
diffusion rate and population values for these parameters are found from this analysis. 
4.2 Subjects and Methods 
4.2.1 Participants 
Data from 17 participants were used in this analysis. The participants were originally recruited 
for the pilot study of DISST (Lotz et al. 2010). Each participant underwent at least two DISST 
tests on separate days. All tests were performed between 9-11am after an overnight fast from 
10pm. The participant‘s weight, height and blood pressure were taken.  
Three different dosing frequencies were used in the pilot study. A low dose test involves an 
intravenous glucose injection of 5g followed by an intravenous insulin injection of 0.5U. A 
median dose test uses 10g of glucose and 1U insulin. A high dose test uses 20g glucose and 2U 
insulin. Table 4.1 summarizes the tests these patients underwent. More details on the patient 
cohort and the pilot study can be found in Lotz (2007) and Lotz et al. (2010). 
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This study was approved by the Upper South Regional Ethics Committee, New Zealand.  
Table 4.1 Participant details summary from the pilot DISST study. 
Group Number 
(M/F) 
Age 
median,[IQR] 
(years) 
BMI  
median, [IQR] 
(kg.m
-2
) 
Test Dose 
low medium high 
NGT* 13 (4/9) 41, [29, 51] 25, [23, 27] 7 24 5 
T2DM/IFG* 4 (1/3) 56, [52, 58] 32, [28, 35] 4 4 2 
*NGT = normal glucose tolerance. T2DM = Type 2 diabetes mellitus. IFG = impaired fasting glucose. 
4.2.2 Test procedure 
Measurements in blood glucose (G), plasma insulin (I) and plasma C-peptide (C) were taken 
during the tests. Initially, glucose was administered as a 50% solution. Insulin was dosed in two 
steps to minimise dilution errors. First, 0.5ml (50U) of insulin (Actrapid, NovoNordisk) was 
drawn in a 1ml syringe and diluted with 49.5 ml saline to obtain a 1U/ml solution. Second, the 
test dose was drawn (0.5ml, 1ml or 2ml) in a 3ml syringe. 
A cannula was inserted into the antecubital fossa. Two baseline blood sample (8 ml) were taken 
at t=-10 and t=0 minutes. Glucose administered at t=0 min and insulin t=10 min just after 
baseline samples taken at those times. Apart from baseline samples, blood was sampled during 
the test at t=5, 10, 15, 20, 25, 30, 35 and 45 minutes. Sampling and administration was 
performed on the same cannula. It was flushed first with the participant‘s own blood, then with 
saline after each bolus input to avoid any contamination. In particular, this approach minimises 
errors due to insulin and glucose binding to inner walls of tubes (NovoNordisk 2002). Each 
participant was given a snack after the test. 
Blood samples were sent to the laboratory immediately or frozen at -80°C. In the laboratory, 
these blood samples were centrifuged and plasma serum was separated for plasma insulin and 
plasma C-peptide. Glucose was analysed by an enzymatic glucose hexokinase assay (Abbott). 
Plasma insulin and plasma C-peptide were analysed with an enhanced chemiluminescence 
immunoassay (ECLIA) (Roche 2004). 
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4.2.3 Participant specific parameter identification 
Participant specific parameter identification is performed in three stages using measured G 
(mmol.L
-1
), I (mU.L
-1
) and C (pmol.L
-1
) data. 
In the first stage, endogenous insulin secretion (Uen) is calculated using the C-peptide model in 
Equations 4.1–4.2 adapted from Docherty et al. (2011). 
 ̇   (     )          4.1 
 ̇          4.2 
In the second stage, participant specific first pass hepatic clearance (xL) and liver insulin 
clearance (nL) are fitted to plasma insulin measurements using insulin and glucose infusions, Uex 
and P. Uen is calculated in the first stage by deconvolution. The pharmacokinetic (ICING) 
models defined in Equations 4.4–4.5 are used in this stage, and a good fit will have modeled I in 
good agreement with plasma insulin measurements. An integral based parameter identification 
method (Hann et al. 2005) is used for commencement identification of xL and nL. 
In the third stage, patient-specific insulin sensitivity (SI) is identified by fitting the 
pharmacodynamic (ICING) model defined in Equation 4.3 to blood glucose measurements using 
identified values from Equations 4.4–4.5 to estimate Q(t) and other known inputs in Equation 
4.3. The same integral fitting method is used for the identification. Finally, it is important to note 
that Equation 4.3 also includes insulin effect saturation in the term αG. The ICING model is thus 
defined: 
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All parameters are a-priori values are defined in Table 4.2. Table 4.3 defines the exogenous 
input for the tests. 
Table 4.2 Parameter values and descriptions for the pharmacodynamics/kinetics (ICING) models and C-
peptide model. 
Parameter Value Unit Description 
G stimulated mmol.L
-1 
Blood glucose concentration 
Q stimulated mU.L
-1 
Interstitial insulin concentration 
I stimulated mU.L
-1 
Plasma insulin concentration 
C stimulated pmol.L
-1 
Plasma C-peptide concentration 
Y stimulated pmol.L
-1 
Interstitial plasma C-peptide concentration 
Uen stimulated mU.min
-1 
Endogenous insulin secretion rate 
pG 0.006 min
-1 
Non-insulin mediated glucose removal 
EGP 1.16 mmol.min
-1 
Endogenous glucose production rate 
CNS 0.3 mmol.min
-1 
Central nervous system glucose uptake 
VG 13.3 L Plasma glucose distribution volume 
VI 3.15 L Plasma and interstitial insulin distribution volume 
αI 0.0017 L.mU
-1 
Hepatic insulin clearance saturation parameter 
nK 0.0542 min
-1 
Renal insulin clearance rate 
nL 0.1578 min
-1 
Hepatic insulin clearance rate 
xL 0.67  Fractional first-pass hepatic insulin extraction 
nI identified min
-1 
Plasma-interstitial diffusion rate 
nC identified min
-1 
Interstitial insulin degradation rate 
αG identified L.mU
-1 
Insulin binding saturation parameter 
SI identified L.mU
-1
.min
-1 
Insulin sensitivity 
k1, k2, k3 a-priori min
-1 
C-peptide transport rates 
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Table 4.3 Exogenous input variables to the pharmacodynamics/kinetics (ICING) models. 
Variable Unit Description 
P mmol.min
-1
 Oral glucose input rate (enteral) 
Uex mU.min
-1 
Exogenous insulin input rate 
 
In the original work of Lotz (2007), VG is also identified, while nK, k1, k2 and k3 are calculated a-
priori via functions of height, weight, gender and age (Van Cauter et al. 1992). Lotz (2007) also 
used different volumes for plasma and interstitial insulin distribution. However, variance in these 
values did not impact participants‘ pharmacokinetics significantly, and were therefore fixed at 
generic population values for this study. 
4.2.4 Grid Analysis of αG and nI 
As αG and nI contribute significantly to the modeled values of Q, both parameters play a critical 
role in that they link this unmeasurable concentration to the measurable concentrations and 
compartments for I and G. However, these two parameters cannot be uniquely identified without 
measurements being available in Q. In reality, the dynamic response of Q is effectively 
unmeasurable (Duckworth et al. 1998; Sherwin et al. 1974).  
This section analyses the relationship of αG and nI parameter values using a grid search method 
to study their influence on SI. The analysis range for nI is [0.001, 0.065] (Duckworth and 
Kitabchi 1981; Nestler et al. 1988), and for αG is [0, 0.1] (Natali et al. 2000; Prigeon et al. 1996; 
Transberg et al. 1981). These ranges cover the physiological ranges reported in literature, where 
the boundaries are beyond reported physiological maximum and minimum levels (Duckworth 
and Kitabchi 1981; Natali et al. 2000; Nestler et al. 1988; Prigeon et al. 1996; Transberg et al. 
1981). 
Specifically, the variations in model-based SI are examined across the grid space of αG and nI 
with the resulting intra-patient repeatability in insulin sensitivity as the optimised metric. An 
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insulin sensitivity test producing the least variation in an individual over multiple tests is usually 
considered to be more accurate. In addition, limiting intra-patient repeatability in modelling the 
DISST to within its reported ~11% CV (Lotz et al. 2008) ensures the analysis does not over- or 
under- fit the data. 
In particular, it assumes the individual is effectively the same to within test repeatability between 
tests, which is both realistic and the best assumption available to ground this analysis. The intra-
patient variability in SI is defined: 
    
∑          ̅ 
∑      
 4.6 
where n is the number of tests conducted on a single patient. 
4.3 Results and discussion 
4.3.1 Fitting and grid-search results 
The fitted SI variance for each subject in the parameter space of αG = 0  0.1 and nI = 0.001  
0.065 generally decreases with increasing nI, and to a lesser degree, decreasing αG. The overall 
variation in SI in the parameter space across the 18 subjects can be seen in Figure 4.1. The intra-
participant variation in SI is generally low within the parameter space studied, as shown in Figure 
4.1(A). The degree of variation is comparable to that for the model-based SI from the original 
pilot study of Lotz (2007), which reported intra-participant variation generally of 11%. The 
darker regions in Figure 4.1(B) are parameter values producing tighter inter-quartile spread of SI 
variability across all subjects. The darker areas are similar to areas of low median variability 
from all patients in Figure 4.1(A). Figure 4.1(C) effectively shows that low αG and low nI results 
in more cohort outliers with large intra-patient variability. 
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Per-patient, the spread of SI variability across the 17 patients can be seen in Figure 4.2(A). The 
combination [αG, nI] = [0, 0.049] represents the population values from the original DISST 
model Lotz et al. (2008). The model-based SI using [αG, nI] = [0, 0.049] in this study correlated 
well to the SI calculated using the original DISST model where more parameters are patient-
specific (Lotz et al. 2008) showing the effect of these changes in assumptions. The correlation of 
SI from the model in Equations 4.1-4.5 with these parameters ([αG, nI] = [0, 0.049]) to the SI 
values from the DISST pilot (Lotz et al. 2010) and when fit to EIC data (Lotz 2007) is a 
combined R=0.93. This high correlation suggests that model accuracy is not compromised by 
adapting population values in parameters which involved patient-specific calculation in the 
original DISST model. The correlation decreases for the other two combinations shown in Figure 
4.2(A), where R=0.85 when [αG, nI] = [0.05, 0.055] is the ‗best fitted‘ model-based parameters 
and R=0.7 when [αG, nI] = [0.015, 0.003] are the values found for a critically ill cohort model-
based parameters (Lin et al. 2011). 
 
Figure 4.1 Variation of model-based SI. Color bars are the level of variations. Darker areas of least 
intra-participant mean SI variability from different DISST tests. (A) Median variability from all 
participants. (B) IQR of mean variability amongst participants. (C) 90% CI in variability amongst 
participants 
A B C 
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The combinations of αG and nI producing the lowest intra-patient SI variability for each patient 
can be seen in Figure 4.2(B). The best combinations from each of the 17 patients are scattered 
widely over the parameter space. This scatter may be an indication that these parameters have 
significant inter-patient variability and patient-specificity in a case with limited structural model 
identifiability. 
The level of saturation in insulin-mediated glucose removal for a given insulin dose has been 
reported across a wide range. The plasma insulin level at half maximal action of glucose removal 
has been reported to be between 50-1000 mU.L
-1
 a range of 20 times. These results are 
effectively equivalent to αG between 0.04 and near zero (Docherty et al. 2010; Natali et al. 2000; 
Nestler et al. 1988; Prigeon et al. 1996; Rizza et al. 1981; Transberg et al. 1981). The saturation 
in insulin-mediated glucose removal may not simply be due to the number of available receptors. 
A delay in insulin transportation to the skeletal muscle in addition to transport delay (nI), 
common in insulin resistant individuals, would also been seen as saturation in insulin-mediated 
glucose removal (Barrett et al. 2009; Prigeon et al. 1996). In addition, the dynamic response of 
endogenous glucose production to the insulin and blood glucose is causing instability to the 
model assumption depending on levels of nutrition and assumptions about the role of SI (Pretty 
2012). Thus, the underestimation of endogenous glucose production will also cause glucose 
Figure 4.2 (A) Cumulative distribution of patient SI variability at different αG and nI values. (B) αG 
and nI values for the lowest SI variability in each patient.  
A B 
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removal to appear slower, effectively adding to the apparent saturation effect in the context of 
the model defines and its underlying assumptions. 
Although the combination of [αG, nI] = [0.015, 0.003] limited the variability of intra-patient SI 
over the cohort, the resulting SI is almost equally high for all patients, losing its diagnostic value 
in insulin resistance screening. The correlation to the original DISST SI dropped significantly to 
R=0.70. The same results are found when extreme values of αG are used. The correlation dropped 
to R=0.78 when [αG, nI] = [0.1, 0.065]. However, the decrease in R value is not as significant as 
lowering nI.  
The combination [αG, nI] = [0.05, 0.055] appears to deliver both good intra-patient variability, 
while maintaining good diagnostic accuracy. This set of parameter values produced low median 
SI variation amongst all subjects where the inter-quartile range is also tight, as seen in Figure 4.1, 
with median 12%, [IQR: 11, 14]%. The correlation to the original DISST SI is R=0.85 and the 
median value of 12% is slightly higher than to the reported value 11% of Lotz et al. (2008) in its 
Monte Carlo analysis of the DISST. It is thus at, or near, the expected minimum value. More 
importantly, the identified SI also follows the same trend as the original DISST SI and identified 
patients with impaired glucose tolerance with similar accuracy ensuring clinical efficacy as well 
as further form of validation. 
A typical DISST test response from a patient is shown in Figure 4.3. The model fits to plasma 
insulin measurements using different parameter values αG and nI are effectively equally good 
across the physiological parameter space. Therefore, patient-specific αG and nI cannot be 
identified simultaneously with nL and xL given that plasma insulin levels are the only 
measurements available. The effect of αG and nI on the shape of insulin at the receptor level (i.e. 
the effective insulin for glucose removal) can be seen in Figure 4.3. Within the physiological 
range, larger αG results in a near uniform shift in the level of receptor bound insulin, whereas 
smaller nI causes the shape of receptor bound insulin to be flatter with a delay in peak time. 
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The level of modeled αG has been found to have a magnified effect in the SI of critically ill 
patients receiving intensive insulin therapy (Chase et al. 2004). It can be seen in Figure 4.3(B), 
varying αG shifts the magnitude of the modeled ―effective‖ insulin without influencing the time 
of peak action. Therefore, αG does not impact the identified value of SI as much as nI. In the 17 
subjects evaluated in this study, including the saturation parameter αG enhanced the repeatability 
of the modeled SI within a patient, as this eliminates the outlying large variability seen in the low 
αG region in Figure 4.1(C). 
The level of nI has both a magnification effect as well as phasing effect on the shape of effective 
insulin. When the level of nI decreases, less insulin is able to reach interstitium before being 
cleared from plasma by the liver and kidneys. The value for nI in the original DISST model was 
calculated using models of C-peptide pharmacokinetics (Van Cauter et al. 1992). Using these 
equations, the values of nI amongst the 17 subjects in this study range between 0.048–0.050. 
Details for this calculation can be found in Van Cauter et al. (1992) and Lotz (2007). A 
population nI value of 0.055 is found to provide good intra-patient repeatability in SI and is in the 
region found by Van Cauter et al. (1992). 
Figure 4.3 Typical DISST (Dynamic Insulin Sensitivity and Secretion Test) test response (A) Plasma 
and effective insulin. Subfigure (B) focuses on the shape of effective (receptor bound) insulin with 
different [αG, nI]. 
A B 
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Figure 4.4 Relative residual (median,IQR) per-patient with mean between measured I (A) and G (B) data 
at different [αG, nI] responses based on the model.  
4.3.2 Validation and relative residual analysis 
In the validation study of the ICING glucose-insulin model, using clinical data from critically ill 
patients receiving intensive insulin therapy, nI was found to be very low at 0.003 min
-1
 (Lin et al. 
2011).  This outcome may indicate significant impaired trans-capillary transport for patients who 
are critically ill. In particular, sepsis causes a dysfunction in mirco-circulation as well as cell 
metabolism, and is a condition that is prevalent in critical care (Abraham and Singer 2007). 
However, Pretty (2012) found that the insulin kinetics parameters are nI = nC = 0.006 min
-1
, 
which is double the values of the Lin et al. (2011) study. These values were optimal in 
minimising the sum of absolute errors between simulated and measured interstitial insulin 
concentration. Nevertheless, the level of saturation in insulin-mediated glucose removal is 
assumed to be constant and unaffected with this new finding. Since these parameters are 
population constants, they are unlikely to alter the overall variability of SI, just its relative value. 
 
 
This study used data from the DISST and an adapted version of its model of the glucose-insulin 
pharmacodynamics model. This latest glucose pharmacodynamics model (Pretty et al. 2012) is 
currently being used in the Christchurch Hospital Intensive Care Unit (Evans et al. 2011; Fisk et 
al. 2012). The main advantage of using this simple model over a multi-compartmental model is 
A 
B 
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Figure 4.5 Cumulative distribution of mean relative residual, I (A) and G (B) for three different cohort 
parameters of [αG, nI].  
the model identifiability using limited plasma samples, while capturing and accounting the 
dominant dynamics of plasma glucose at cohort level. This model has performed well in a 
variety of insulin and nutrition based glycaemic control trials (Chase et al. 2011a; Evans et al. 
2011; Fisk et al. 2012). The trade-offs between the improved structural identifiability of a 
simplified model and potential fitting errors introduced by simplification of the model are 
insignificant as the relative residual observed in fitting G responses for each patient is 
comparatively small as shown in Figure 4.4(B).  
 
 
Larger population mean relative residuals in I (Table 4.4) indicate high inter-patient variability in 
modelling and fitting plasma insulin based on measured insulin data as shown in Figure 4.4(A). 
Based only on population parameters of [αG, nI], the model-based compartment is unable to 
capture the underlying dynamics behind it. However, the modeled dynamics appear similar as 
Figure 4.2 clearly shows that low variability in model-based SI is achievable via participant-
specific parameters identification for [αG, nI]. Comparatively, median relative residual for I is 
higher than G as in Figure 4.5. Importantly, the 90% confidence interval of the residuals in 
Figure 4.5 are all at or within measurement error for their respective species. 
A B 
45 
 
For cases of poor fit, it may be suspected that a contributor to these poor fits is caused by 
differences in incretin effects for each subject. Incretins affect the endogenous insulin 
secretion/production (Uen) response to change in glucose concentration. Previous results from 
Despopoulos and Silbernagl (2003) verified C-peptide, just like insulin, is produced by the β-
cells located in the islets of Langerhans (pancreas). However, C-peptide is only cleared by renal 
and thus, has longer half-life in comparison to insulin (Guyton and Hall 2000). To this point, 
plasma C-peptide concentrations are still the best indication of pancreatic insulin secretion due to 
equimolar secretion and longer half-life.  
Table 4.4 Population mean relative residual summary at different [αG, nI] values. 
                     Mean Relative 
                        Residual (%) 
Cohort [αG, nI] 
Median [IQR] 90% CI 
G I G I 
DISST [0,0.049] 4 [3,7]% 5 [-24,2]% [0,12]% [-88,13]% 
ICING (ICU) [0.015,0.003] 3 [4,7]% 6 [-19,1]% [3,12]% [-65,16]% 
Best fitted [0.05,0.055] 4 [4,7]% 2 [-27,0]% [1,12]% [-98,9]% 
 
Fairly good fit in modeled I is obtained by grid search analysis with median at 2% of mean 
relative residual when αG=0.05 and nI=0.055. However, the model still delivers good fit with 
other combinations of [αG, nI] at a cohort level. Thus, the pharmacodynamics/kinetics model can 
tolerate a range of any combinations of [αG, nI] that covers most physiological ranges reported in 
literature indicating the aforementioned lack of structural identifiability used to justify the grid 
search used. In particular, parameter identification trade-off between these parameters causes 
unique identification to be impossible. The inabilities to discover this relationship at an inter-
patient level suggested that there are still underlying effects that contribute to this uncertainty. 
These effects might be from human physiology or/and in modelling methodology (Chase et al. 
2011b; Cobelli et al. 2007; Docherty et al. 2011).     
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4.4 Summary 
This chapter presented an independent examination of the model roles of αG and nI for describing 
insulin and glucose pharmacodynamics and pharmacokinetics. Interstitial insulin kinetics and 
their influence on model-based insulin sensitivity observation was analysed using data from the 
clinical pilot study of the dynamic insulin sensitivity and secretion (DISST) test and the glucose-
insulin PK-PD models. From these inputs, a model of interstitial insulin dose-response that best 
links insulin action in plasma to response in blood glucose levels was developed. The critical 
parameters influencing interstitial insulin pharmacokinetics (PKs) are saturation in insulin 
receptor binding (αG) and the plasma-interstitium diffusion rate (nI). The optimal population 
values for these parameters are found to be [αG, nI]=[0.05,0.055]. 
However, increasing the number of identified participant-specific parameters did not necessarily 
improve model accuracy, as inter-patient fitting error in plasma insulin was quite high compared 
to fitting error in plasma glucose.  
The intra-patient repeatability of SI and its link to interstitial insulin action is studied in 17 
patients. Very low values of insulin receptor saturation αG and very low values of plasma-
interstitial insulin diffusion nI are found to produce the most intra-patient variability in SI. A 
model accounting for insulin receptor saturation enhanced the repeatability in SI. A cohort of 
patients with mixed levels of insulin resistance will also further validate the accuracy of the 
model-based SI and may provide a better understanding of the contributing factors of insulin 
resistance. ―Customising‖ patient-specific identification on αG and nI might suggest the best 
repeatability in SI. This might also increase model fitting accuracy of plasma insulin and 
interstitial insulin. 
However, more test data from larger cohorts will enable a more in-depth study of saturation in 
mediated glucose removal and plasma-interstitium insulin diffusion, or the actions of insulin in 
the interstitium in general. Once pharmacokinetics and pharmacodynamics of plasma insulin and 
interstitial insulin are better measured and understood, it may refine the understanding of 
endogenous insulin production covering the incretin effects. 
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Chapter 5. Incretin Effects of Critically Ill Patients  
Critically ill patients are regularly fed via constant enteral (EN) nutrition infusions. The impact 
of incretin effects on endogenous insulin concentration in this cohort remains unclear. This 
chapter investigates whether EN-driven incretin effects should alter insulin and glycemic 
management in critically ill patients. 
5.1 Introduction 
Critically ill patients exhibit increased gluconeogenesis, reduced insulin secretion and increased 
insulin resistance, resulting in hyperglycaemia, increased complications and increased risk of 
mortality (Capes et al. 2000; Van den Berghe et al. 2001). Studies show that glycaemic control 
can mitigate these outcomes (Krinsley 2004; Van den Berghe et al. 2001). However, intensive 
insulin therapy can also lead to increased hypoglycaemia and mortality (Bagshaw et al. 2009b; 
Chase et al. 2011a). Variable patient-specific levels of endogenous insulin secretion play a role 
in this variability, particularly in early, acute phases of care (Bagshaw et al. 2009a).  
In addition, the route used for the provision of nutrition can also influence the effect of intensive 
insulin therapy. A recent meta-analysis (Marik and Preiser 2010) demonstrated that intensive 
insulin therapy was not associated with an improved outcome when enteral nutrition was used as 
the predominant source of calories. This finding is consistent with the presence of an incretin 
effect, i.e. the stimulation of endogenous insulin secretion by enteral feeding. 
The incretin effect plays an important role in glucose homeostasis in healthy subjects (Schirra et 
al. 1996). In particular, as noted in Chapter 2, incretin enhances the postprandial appearance of 
endogenous insulin (Holst and Gromada 2004; Muscelli et al. 2008; Nauck et al. 1986; Vilsbøll 
and Holst 2004). The underlying mechanisms involve the release of gastrointestinal hormones 
gastric inhibitory peptide (GIP) and glucagon-like peptide-1 (GLP-1), which are released from 
the intestinal muscosa when glucose is ingested (Faber et al. 1979; Holst and Gromada 2004; 
McIntyre et al. 1965; Nauck et al. 1986; Perley and Kipnis 1967; Schirra et al. 1996). As a 
result, insulin secretion is enhanced in excess of what would have been released if the glucose 
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were administered parenterally via intravenous lines (Dalla Man et al. 2006; McIntyre et al. 
1965; Perley and Kipnis 1967). More specifically, studies have shown that the incretin effect can 
enhance the insulin response to oral glucose by 50–70% in comparison to an equivalent IV dose 
(Nauck et al. 1986; Whyte et al. 2010).  
Although many incretin effect studies have addressed the distinct physiology of diabetic and 
non-diabetic individuals (Dalla Man et al. 2010; Holst and Gromada 2004; Muscelli et al. 2008; 
Nauck et al. 2004; Perley and Kipnis 1967), the incretin effects has not been observed in a 
critically ill cohort. Critically ill patients are typically fed with constant EN infusions. Hence, it 
is possible that there is no incretin effect observable in these patients, who otherwise display 
significantly enhanced endogenous insulin secretion (Pretty 2012; Whyte et al. 2010). Equally, 
their highly counter-regulated state and wide range of insulin secretion rate (Capes et al. 2000) 
may result in a blunting of this responses, as seen similarly in individuals with type 2 diabetes 
(Muscelli et al. 2008). 
This analysis uses dense clinical data and a model-based analysis to observe incretin effects by 
tracking the identified model-based insulin sensitivity (SI) in a cohort of critically ill patients. It 
is hypothesised that the identified SI would decrease during interruptions of EN and would 
increase when EN is resumed, where, for short periods around transition, the true patient SI 
would be assumed constant. Thus, changes in modeled SI given the fixed assumed endogenous 
secretion by the model would support the presence of an EN-related incretin effect in the 
population of non-diabetic, critically ill patients studied. 
5.2 Subjects and Methods 
5.2.1 Patient cohort 
Data was obtained earlier from the Specialized Relative Insulin Nutrition Titration (SPRINT) 
study (Chase et al. 2008). Blood glucose concentration (G) and EN nutrition data from 371 
critically ill patients on SPRINT protocol were used. These 371 patients were undergoing 
SPRINT tight glycaemic control (TGC) where insulin and nutrition are given in balance based on 
the response to the prior insulin and nutrition intervention (Chase et al. 2010; Lonergan et al. 
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2006). Hence, the protocol prevents hyperglycaemia by matching the nutrition and exogenous 
insulin given to the body‘s patient-specific ability to utilise them.  
For this study, patient inclusion required a minimum of 10 hours of EN feeding, followed by at 
least 7 hours with EN off, and then at least 5 hours of resumed feeding. Hence, only 52 of 371 
SPRINT patients‘ were eligible for analysis. Patients with diabetes (N=64) were excluded due to 
irregularity of the incretin effect that common only occurs in diabetes (Muscelli et al. 2008; 
Nauck et al. 2004; Nauck et al. 1986). Another 255 non-diabetic patients were excluded as they 
did not have a period of zero EN input. The clinical details of this selected cohort (N=52), 
including baseline variables, Acute Physiology and Chronic Health Evaluation (APACHE) II 
scores and APACHE III diagnosis codes are summarised in Table 5.1. Data from the excluded 
non-diabetic patients (N=255) is included for comparison. 
Table 5.1 SPRINT cohort baseline variables summary. Data expressed as median [IQR] (APACHE = 
Acute Physiology and Chronic Health Evaluation). 
Patient Data from SPRINT 
 Excluded, non-Diabetic  
cohort 
Included  
cohort 
 
 N=255 *N=52  
Age (years) 65 [51-74] 65 [49-72] p=0.86 
% Male 70% 67% p=0.67 
APACHE II score 18 [14-23] 19 [17-28] p=0.07 
APACHE III Diagnosis Number of cohort (%) 
Cardiovascular 38 (15%) 5 (10%) 
Respiratory 64 (25%) 8 (15%) 
Pancreatitis 11 (4%) 7 (13%) 
Neurological 21 (8%) 6 (12%) 
Trauma 38 (15%) 6 (12%) 
Sepsis 12 (5%) 7 (13%) 
Other (Renal, metabolic, orthopaedic) 71 (28%) 13 (25%) 
*N=52 are the patient data used in this study. Note N=255 and N=52 excluded diabetic data. p-values based on ranksum test. 
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5.2.2 EN feeding criterion 
The transition off EN (ON/OFF) is defined when EN nutrition given to the patient is stopped, 
while the (OFF/ON) transition denotes when EN is recommenced, as illustrated in Figure 5.1. 
These times are known to within a maximum of ±30 min from patient‘s chart data. The glucose 
input from EN infusion varies from 0 to 1.65 mmol.min
-1
 where the range of patient-specific 
goal nutrition rates is 0.4–0.8 mmol.min-1 (Chase et al. 2008). The EN formulation was either 
from Glucerna
®
 1.2 CAL (Abbott 2005) or RESOURCE
®
 Diabetic (Novartis 2005). The specific 
nutrition compositions are given in Table 5.2. 
Table 5.2 Enteral nutrition composition based on GLUCERNA
®
 1.2 CAL and RESOURCE
®
 Diabetic 
(Novartis). 
 Glucerna
®
 1.2 CAL  
(Abbott) 
RESOURCE
®
 Diabetic 
(Novartis) 
Carbohydrate (Fiber) 35 % (16 g/1000 mL) 36 % (12 g/1000 mL) 
Protein 20 % 24 % 
Fat 45 % 40 % 
 
The ON/OFF and OFF/ON EN transitions are defined: 
EN (ON/OFF) transition: Transition between minimum of 10 hours on EN feeding and followed 
by at least 7 hours off EN feeding. 
EN (OFF/ON) transition: Transition between minimum of 7 hours off EN feeding and followed 
by at least 5 hours of resumed EN feeding. 
where Figure 5.1 illustrates an example of the EN nutrition input rate during SPRINT TGC 
protocol. The EN feeding is stopped at t=118 hours and EN feeding is resumed after 7 hours off 
feed at t=126 hours. 
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Figure 5.1 The ON/OFF and OFF/ON EN transitions. (P(t)) showing rate (P(t)) on the y-axis and time 
(hours) along x-axis. 
All critically ill patients that underwent SPRINT were continuously infused with EN feeding in 
balance with the insulin input to prevent hypoglycaemia and/or hyperglycaemia. SPRINT 
controls both insulin and nutrition inputs. Specifically, SPRINT modulates nutritional intake 
between 30–100% of patient-specific goal feed rate based on ACCP/SCCM guidelines (Cerra et 
al. 1997). SPRINT also specifies only low-carbohydrate EN nutrition formula with 35–40% 
carbohydrate content, as shown in Table 5.2, unless clinically specified otherwise in rare cases. 
Importantly, SPRINT determines both insulin and nutrition interventions 1-2 hours based on 
estimated insulin sensitivity of the patient in response to the prior interventions, rather than 
depending on blood glucose concentrations or/and changes alone. Hence, insulin and nutrition 
are given in accordance with explicit knowledge of carbohydrate intake, which is unique to this 
protocol (Suhaimi et al. 2010). The overall mechanism thus matches the nutrition and exogenous 
insulin infused to the body‘s patient-specific ability to adequately utilise them, which resulted in 
better control and a reduction in hypoglycaemia (Chase et al. 2008). 
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5.2.3 Identification of SI 
Patient-specific SI is identified assuming constant model-based endogenous insulin secretion 
because insulin secretion cannot be directly measured at bedside in real-time to guide therapy. 
This assumption is used to measure the presence of an incretin effect. SI is identified hourly 
using the iterative integral method (IIM) (Docherty et al. 2010) and validated clinical data from 
SPRINT TGC protocol.  
The clinically validated Intensive Control Insulin-Nutrition-Glucose (ICING) model Equations 
5.1-5.6 presented by Lin et al. (2011) is used to identify hourly SI (L.mU
-1
.min
-1
) from each 
patient‘s clinical data: 
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All ICING model parameters are based on population values of critically ill patients (Lin et al. 
2011), which are defined in Tables 5.3 and 5.4. 
Table 5.3 Parameter (stimulated) values and descriptions for the ICING model. 
Variable Value Unit Description 
G stimulated mmol.L
-1 
Blood glucose concentration 
Q stimulated mU.L
-1 
Interstitial insulin concentration 
I stimulated mU.L
-1 
Plasma insulin concentration 
P1 stimulated mmol
 
Glucose appearance in the stomach 
P2 stimulated mmol
 
Glucose appearance in the gut  
P stimulated mmol.min
-1 
Glucose appearance in blood from EN nutrition 
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Table 5.4 Parameter values and descriptions for the ICING model. 
pG 0.006 min
-1 
Non-insulin mediated glucose removal 
EGP 1.16 mmol.min
-1 
Endogenous glucose production rates 
CNS 0.3 mmol.min
-1 
Central nervous system glucose uptake 
VG 13.3 L
 
Plasma glucose distribution volume 
VI 4.0 L Plasma and interstitial insulin distribution volume 
αG 0.0154 L.mU
-1 
Insulin binding saturation parameter 
αI 0.0017 L.mU
-1 
Hepatic insulin clearance saturation parameter 
nI 0.006 min
-1 
Trans-endothelial diffusion rate 
nC 0.006 min
-1 
Interstitial insulin degradation rate 
nK 0.0542 min
-1 
Renal insulin clearance rate 
nL 0.1578 min
-1 
Hepatic insulin clearance rate 
xL 0.67 1 Fractional first-pass hepatic insulin extraction 
d1 0.0347 min
-1 
Glucose transport rate from stomach to gut 
d2 0.0069 min
-1 
Glucose transport rate from gut to plasma 
Pmax 6.11 mmol.min
-1 
Maximum glucose flux from gut to plasma 
Uen 1000 mU.min
-1 
Endogenous (basal) insulin secretion 
PN a-priori mmol.min
-1 
Parenteral nutrition input rate (Intravenous) 
D a-priori mmol.min
-1 
Enteral nutrition (dextrose) input rate 
Uex a-priori mU.min
-1 
Intravenous insulin input rate 
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5.2.4 Data analysis and observation of incretin effect 
A notable reduction in model-based SI after the ON/OFF transition implies an un-modeled 
decrease in the rate of endogenous insulin secretion due to the loss of incretin effects when feed 
is stopped rather than a true reduction of physiological SI. In contrast, an increase in observed SI 
implies an incretin effect at the OFF/ON transition when the feed is commenced. The SI change 
(ΔSI) across the ON/OFF and OFF/ON transitions indicates an incretin effect as its stoppage for 
this analysis. ΔSI was calculated as: 
     
  ( )     
  ( )     
 5.7 
The blood glucose changes, ΔG, over these periods were also calculated similarly.  
The analysis uses a 3-hour moving average to reduce the effect of measurement error, noise and 
the influence of transient effects caused by cohort-constant assumption of these model terms. SI 
profiles are derived over periods starting 3 hours before a transition until 5 hours after the 
transition. The 5-hour limit allows full gut emptying after ON/OFF transition or full resumption 
of the effect EN after the OFF/ON transition. Between these times, an incretin effect would show 
a steady biased shift in SI, if it exists. Results are illustrated via Bland–Altman plots, while 
Wilcoxon rank sum tests (p-values) are used to compare distributions and the significance of any 
shift in SI(t) over the cohort. 
The changes in plasma insulin via insulin secretion and activation by the liver were assumed to 
be observable through changes in measured SI (Lin et al. 2011). The variability observed was 
outside the normal variation, which is centred around zero (Lin et al. 2008). Thus, any incretin 
effect is assessed using the shift in SI after EN feed transitions, as a surrogate, rather than from a 
direct insulin measurement. It could be concluded that insulin sensitivity changes are a more 
efficient indicator for post-hepatic endogenous insulin appearance (Nauck et al. 1986), given the 
two possible outcome causes noted 
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5.3 Results and Discussion 
5.3.1 SI correlations over EN transitions 
SI correlations over the ON/OFF (r=0.49, median=-36%, p=0.0001) and OFF/ON (R=0.60, 
median=31%, p=0.03) transitions for t=4 hour are shown in Figure 5.2(A and B). The changes of 
SI at two EN transitions of ON/OFF in Tables 5.5 and OFF/ON in Table 5.6 are evidenced by the 
bias about the equality line. Figure 5.2(A and B) shows the diversity of ΔSI across both 
transitions. 
Figure 5.2 The distributions of SI for two transitions of ON/OFF (A) and  OFF/ON (B) EN transitions at 
the centred time averages of t=-2 and t=4 hour (N=52). (Note the log-scale). 
Tight and dense SI distribution is observed in Figure 5.2(B) at the OFF/ON transition implies that 
resuming EN nutrition causes measurable changes in insulin secretion in response to EN 
nutrition input for a majority of the patient studied. While at the ON/OFF transition, the SI 
distribution in Figure 5.2(A) around the median line shows a modest number of confounders who 
behave differently. 
Table 5.5 summarises ΔSI at the ON/OFF transition across the cohort. SI decreased after the 
ON/OFF transition until t=4 hour, where it settled to a median reduction of -36%. The right-most 
A B 
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column shows the rate of confounders (ΔSI > 0). This implies that inter-patient or intra-patient 
variation obscures the observation or that the effect itself if it is not always observable.  
Table 5.5 Summary of proportional change of blood glucose, ΔG, and insulin sensitivity, ΔSI, at ON/OFF 
feed transition (N=52). 
ON/OFF 
 
t* (hour) 
Blood Glucose (ΔG) Insulin Sensitivity (ΔSI) 
Median IQR p-value Median IQR p-value SI (↑) 
-2 0% [0,0]% 1.0 0% [0,0] 1.0 50% 
-1 0% [-3,6]% 1.0 0% [-10,12]% 0.9 50% 
0 -1% [-9,5]% 0.7 -2% [-16,18]% 0.7 46% 
1 -2% [-12,8]% 0.6 -9% [-30,23]% 0.3 38% 
2 -1% [-12,9]% 0.6 -10% [-45,15]% 0.05 27% 
3 -4% [-15,10]% 0.5 -29% [-59,15]% 0.01 29% 
4 0% [-16,17]% 0.4 -36% [-82,24]% 0.001 37% 
*Times are 3-hour averages centred at the time shown, and the feed transition between t = -1 and 0. EN feed is stopped anytime between t = -1 
and t = 0. 
When EN nutrition stopped, significant ΔSI was observed from t=2 hours (p < 0.05). ΔSI implies 
that insulin secretion response is decreasing after EN nutrition stopped to maintain 
normoglycaemia. Importantly, at this state incretins are suppressed which reduces insulin 
secretion and thus modeled SI relative to the fixed model-based value assumed. Thus, the model 
performance in tracking incretin effect via SI is indistinct at the ON/OFF transition although it is 
sign that at t=2 hours, ΔSI=-10% and t=4 hours, ΔSI=-36% with 37% of confounders‘ exhibiting 
a confounding increased SI. 
The computed ΔSI after the OFF/ON transition are shown in Table 5.6. Median ΔSI increased by 
32% [IQR: -1 to 60%] at t=3 hour after the OFF/ON EN transition. A slightly stronger incretin 
effect is observed at OFF/ON feed transition with only 25% of patients confounding expectation. 
The insulin response to EN glucose was noticeably enhanced after the OFF/ON transition, most 
likely as a result of the concomitant actions of incretins and neural responses to EN nutrition. 
The predominant effect of incretin hormones is to enhance the endogenous insulin secretion that 
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is triggered when the β-cells are exposed to rapid increases in glucose flux (Cobelli et al. 2007). 
At a cohort level, ΔSI stabilised at t=4 hour after EN transitions as the feed was designed for 
enhanced glycaemic stability via slow ingestion (Abbott 2005; Novartis 2005). Hence, both 
transitions should have excited a change, but the OFF/ON transition may have observed better or 
more rapid change due to the essentially fasted patient state. 
Table 5.6 Summary of proportional change of blood glucose, ΔG, and insulin sensitivity, ΔSI, at OFF/ON 
feed transition (N=52). 
OFF/ON 
 
t* (hour)
 
Blood Glucose (ΔG) Insulin Sensitivity (ΔSI) 
Median IQR p-value Median IQR p-value SI (↓) 
-2 0% [0 0]% 1.0 0% [0 0]% 1.0 50% 
-1 -1% [-6,2]% 0.6 4% [-13,12]% 0.9 39% 
0 -1% [-9,6]% 0.9 8% [-14,23]% 0.9 40% 
1 -3% [-11,7]% 0.6 14% [-5,29]% 0.5 33% 
2 -2% [-10,15]% 0.9 25% [-10,46]% 0.3 29% 
3 1% [-12,15]% 0.7 32% [-5,53]% 0.05 32% 
4 6% [-15,18]% 0.5 31% [-1,60]% 0.03 25% 
*Times are 3-hour averages centred at the time shown, and the feed transition between t = -1 and 0. EN feed is stopped anytime between t = -1 
and t = 0. 
Patients were effectively in the fasting state before EN nutrition recommenced between t=-1 and 
0 hours at the OFF/ON transition. As EN nutrition re-started, modeled SI increased significantly 
at t=3 to t=4 hour (p < 0.05) with a 25% confounder rate. Thus, insulin secretion was also 
increased in response to EN nutrition input via the unsuppressed incretin hormones (Holst and 
Gromada 2004; Schirra et al. 1996; Vilsbøll and Holst 2004) to maintain glucose homeostasis. 
Overall, the incretin effects are distinctly observable at the ON/OFF transition given ΔSI rise. 
Bland–Altman representations of the ΔSI changes between t=-2 and t=4 hours are shown in 
Figure 5.3 for both the ON/OFF and OFF/ON transitions. Only 3 patients clearly showed high 
ΔSI measurements (>100%). These patients were diagnosed with either sepsis or pancreatitis and 
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are shown with separate markers. Both conditions significantly affect endogenous insulin 
secretion independently and may well account for these very large changes. 
Figure 5.3 The Bland–Altman of the averages of proportional change SI after the ON/OFF (A) and 
OFF/ON (B) EN transitions at the centred time averages of t=-2 and t=4 hour (N=52). 
The Bland–Altman plots of ΔSI (Figure 5.3) show that the few larger outliers were diagnosed 
with chronic diseases that influence the pharmacodynamics of insulin and glucose. Patient with 
sepsis, trauma and pancreatitis can exhibit more drastic SI changes (Carlson 2003) due to 
excessive counter-regulatory and acute immune response, as well as the direct affect on secretion 
with pancreatitis. Hence, the variability of the results was somewhat expected. The analysis 
without these 3–5 subjects did not change the overall results. 
In addition, studies show that many metabolic abnormalities associated with stress, injury or 
infections were related to loss of tissue sensitivity to insulin (Carlson 2003). Sepsis, trauma and 
other clinical states are characterised by a strong counter-regulatory hormone response. These 
hormone responses are believed to induce insulin resistance in vivo, although some clinical 
studies failed to demonstrate correlations between counter-regulatory hormone response and 
defective insulin-mediated glucose disposal (Thorell et al. 1999). However, the overall evidence 
is still inconclusive concerning the exact cellular and molecular mechanisms underlying insulin 
A B 
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resistance in critical illness and their relationship to the observed metabolic abnormalities 
(Thorell et al. 1999). 
The shifts in G after the ON/OFF and OFF/ON transitions between t=-2 and t=4 hours are shown 
in Bland-Altman format in Figure 5.4. The maximal median G shift across the cohort was -4% at 
the ON/OFF transition and 6% at the OFF/ON transition when t=3 and t=4 hour respectively. 
Median difference between these two transitions was approximately -1% at t=-1, 1 and 2 hour 
indicating tight consistent glucose levels across the cohort. The few patients outside the 90% 
confidence interval (CI) were identified as having pancreatitis or similar disease that 
significantly affects insulin secretion and thus, potentially, this analysis, as listed previously. 
Figure 5.4 The Bland–Altman of the averages of proportional change G after ON/OFF (A) and OFF/ON 
(B) EN transitions at the centred time averages of t=-2 and t=4 hour (N=52). 
In both cases, G remains effectively constant with only small changes. Hence, the impact of the 
incretin effect on glycaemic control was quickly accounted for by the SPRINT TGC protocol. 
More specifically, ΔG changes were insignificant over these transitions indicating there was no 
bias to this factor in the model-based analysis. Equally, this model and SI metric have been 
clinically validated on independent matched cohorts (Chase et al. 2010) in several clinical TGC 
A B 
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studies (Chase et al. 2007; Evans et al. 2011; Fisk et al. 2012; Suhaimi et al. 2010) and against 
the gold-standard EIC (Lotz et al. 2008; McAuley et al. 2011). 
5.3.2 Model fitting 
Measured glucose data, EN model input data as well as ICING model fits of G, I, Q, SI and P are 
shown in Figure 5.5(A,B and C) for a typical case. The incretin effect, as hypothesised, is 
observed directly via ΔSI at the ON/OFF and OFF/ON EN transitions. 
 
Figure 5.5 A typical patient‘s fitted profile. (A) Blood glucose, plasma insulin and interstitial insulin 
fitted profiles. (B) Nutrition (EN) rate (C) time variant insulin sensitivity (SI).  
The ICING model used in this analysis is more explicitly physiological relevant without 
increasing the number of patient-specific parameters to be identified. More importantly, this 
approach allows SI be uniquely identified via patient-specific with limited availability of 
measured data to 1-2 hourly G measurements. The practical model identifiability is quite strong 
despite the limited data available and many population assumptions required to uniquely 
identified SI (Docherty et al. 2011; Lin et al. 2011). However, the model structure 
physiologically relevant and, clinically, the model thus uses and identifies only a single relevant 
parameter compared to other pharmacokinetics and pharmacodynamics models (Hovorka et al. 
2004; Parker and Doyle 2001). It is also able to accurately capture the highly dynamic response 
in critical illness i.e. incretin effects by tracking SI changes. The low and tightly distributed, 
 A 
B 
C 
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prediction errors reported for this model are within the clinical measurement error of 7–12% 
(Chase et al. 2010; Fisk et al. 2012), and signify the model is specifically customised to patient-
specific behaviour in the real-time. In addition, the model ant the SI parameters were extremely 
cross validated in a study by Chase et al. (2010). 
5.4 Limitations 
Incretin effects were observed and isolated in this analysis using EN nutrition changes and the 
study did not directly measure gastrointestinal hormone (GLP-1 and GIP) concentrations. Thus, 
the relative insulin secretion across PN/EN feeds must be measured to directly elucidate the 
incretin effects. However, this analysis provides good evidence for the existence and 
measurement of these effects, meriting the measurement of these hormones. 
5.4.1 PN feeding and Uen secretion  
This analysis only examined changes in SI about EN feeding transitions. Limited PN data (N<6 
patients) limited observation of the incretin effect to those patients with EN according to its most 
commonly used definition in comparison to PN. In this study, the SPRINT glycaemic control 
protocol also modulates enteral dextrose carbohydrate to aid control of hyperglycaemia, rather 
than the characterising the overall nutritional profile. Hence, a cross-over analysis with PN was 
not possible. A study conducted by Casaer et al. (2011) found that a high glucose loading, via 
PN, with inadequate glycaemic control is associated with increased morbidity and mortality. 
Thus an ideal study design for the observation of incretin in critically ill patients would also use 
PN feeding in a cross-over format. However, this format might have ethical limitations. In 
contrast, future studies could incorporate direct measurement of the incretin hormones, such as 
GIP and GLP-1. This approach would also allow direct incorporation and identification of 
additional incretin hormone-related model parameters, as well as direct measurement of the 
effect without relying on PN analysis. 
It is generally accepted that intravenous parenteral (PN) nutrition prompts a lesser level of 
endogenous insulin secretion than EN nutirion (Muscelli et al. 2008), and thus may limit the 
incidence of hypoglycaemia due to unmodeled but enhanced insulin secretion resulting from 
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incretin effects. Plasma insulin responses to glucose given by gastric or jejunal intubation were 
significantly greater than those seen after IV infusion of the same glucose load in some studies 
(McIntyre et al. 1965). Likewise, Petrov and Zagainov (2007) reported a higher prevalence of 
hyperglycaemia during parenteral than enteral nutrition. Hence, if the risk of hyperglycaemia 
could be mitigated via advanced modelling methods, the potential benefits of the incretin effect 
could aid patient recovery. In addition, enteral nutrition is also associated with a significantly 
lower incidence of infection, sepsis and bacterial translocation that may reduce the need for 
surgical interventions to control pancreatitis and a reduced length of hospital stay (Marik and 
Raghavan 2004).  
5.4.2 GLP-1 and GIP hormones 
GLP-1 and GIP are both incretin hormones regulating postprandial insulin secretion. It is 
reported that both incretin hormones released from the gut, are essential in maintaining 
normoglycaemia and glucose homeostasis (Nauck et al. 1986; Schirra et al. 1996; Vilsbøll and 
Holst 2004). Conventionally, the incretin effect is evaluated by comparing the insulin and C-
peptide concentrations to isoglycaemic oral and intravenous glucose tests (Nauck et al. 1986) 
which the increased insulin and C-peptide response during oral feeding defined as degree of the 
incretin effect. 
Some studies found that postprandial GIP concentrations are higher than GLP-1 concentrations. 
However, others found GIP and GLP-1 are equally potent with respect to insulin secretion 
(Scrocchi et al. 1996), whereas some finding clarified GLP-1 to be three to five times more 
potent than GIP (Nauck et al. 1993; Toft-Nielsen et al. 1998). Previous studies also have 
investigated that GIP does not affect insulin secretion at fasting plasma glucose concentrations 
(Nauck et al. 1993; Nauck et al. 1997). Conversely, GLP-1 concentration in the fasting state and 
during an oral glucose challenge is considerably lower (Nauck et al. 1993). Thus, the 
contributions of GIP and GLP-1 to the incretin effects even in normal physiological condition 
with small changes in glucose concentrations remain unclear. 
Modeling GLP-1/GIP with respect to insulin secretion and β-cell glucose sensitivity could 
potentially validate all the assumptions in evaluating the incretin effects. This proposed approach 
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will validate the finding presented here, as it will allow simultaneous estimation of both β-cell 
glucose sensitivity and the ability of GLP-1 and GIP to enhance insulin secretion. Hence, this 
study provides motivation and estimate of effect size and confounders to design such a study. 
5.5 Summary 
The findings of this analysis show the distinct existence of an incretin effect as an observable 
aspect of critically ill patient physiology. The findings were consistent with the presence of an 
EN-related incretin effect in a majority of critically ill patients. Clinically, the existence of this 
effect at EN nutrition transitions should also be considered in the management of glycaemia and 
could influence design of this therapy. Finally, while the results observed valid surrogates of the 
incretin effects, a prospective study with direct measurement and powered by these results may 
be required to confirm the outcomes directly. 
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Chapter 6. Endogenous Insulin Secretion Control Model 
This chapter investigates the relationship between endogenous insulin secretion and changes in 
glucose concentrations using a proportional-derivative (PD) control model. The proposed control 
model is designed to investigate the endogenous insulin secretion amongst subjects with different 
metabolic states: normal glucose tolerance (NGT), impaired glucose tolerance (IGT) and type 2 
diabetes mellitus (T2DM). The underlying effects that influence insulin secretion i.e. incretin 
effects are also defined by tracking the control model gain/response and the identified insulin 
sensitivity (SI). 
6.1 Introduction 
Glucose homeostasis is primarily achieved by a balance between β-cell secretory function and 
insulin dynamics in cells and tissues. The two most common groups associated with the 
metabolic syndrome are IGT and T2DM that are characterised by IR and/or defects of β-cell 
function (DeFronzo et al. 1979). Thus, numerous tests have been developed to assess glucose 
induced insulin secretion and glucose-insulin pharmacodynamics/kinetics.  
The close and inverse relationship between insulin secretion and insulin sensitivity has been 
widely acknowledged only during recent years (Bergman et al. 2002; Cobelli et al. 2007; 
Docherty et al. 2009; Toffolo et al. 1999). An attempt at finding a mathematical relationship 
between insulin sensitivity and pancreatic sensitivity to glucose was described by Bergman et al. 
(1981). Although, the application of modelling to clinical research has been slow, the 
intravenous (IV) glucose with minimal model simplified models has been the most frequently 
used approach (Breda et al. 2001; Pacini et al. 1998; Toffolo et al. 2001). 
It is known that oral glucose stimulates insulin secretion over and above intravenous glucose 
(McIntyre et al. 1965; Perley and Kipnis 1967), and that the gastrointestinal hormones play an 
important role. These hormones (incretins) known as glucagon-like peptide (GLP-1) and glucose 
dependent insulinotropic polypeptide (GIP), which enhanced the endogenous insulin secretion 
(Nauck et al. 1986; Vilsbøll and Holst 2004). GLP-1 and GIP are released from β-cells of the 
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islets of Langerhans in the pancreas following oral glucose consumption or meal, and each has 
shown to potentiate glucose-dependent insulin secretion. The insulinaemic GLP-1 response is 
blunted and the β-cell response to GIP is impaired in diabetic individuals (Muscelli et al. 2008; 
Nauck et al. 1986; Nauck et al. 1993; Toft-Nielsen et al. 1998). Hence, impaired incretin effects 
contribute to the β-cell incompetence of diabetes (Nauck et al. 1986). A study proved that 
introducing GLP-1 hormone can normalise blood glucose of diabetic individuals by stimulating 
glucose-induced insulin secretion, which has strengthened the incretin theory (Creutzfeldt and 
Ebert 1985; Deacon 2012; Hermansen et al. 2002).    
Quantitative indices of insulin secretion can also be defined by plasma C-peptide concentrations 
in response to changes in glucose concentration which elucidate insulin sensitivity (Cretti et al. 
2001; Mari et al. 2002). As C-peptide is equimolarly released with insulin but not degraded in 
the liver (Rubenstein et al. 1969) it is possible to evaluate insulin secretion via C-peptide models 
(Eaton et al. 1980; Van Cauter et al. 1992). Thus, exploiting particular mathematical models of 
insulin kinetics, glucose-insulin dynamics and C-peptide kinetics models would provide direct 
measurement of pancreatic β-cell secretion and hepatic insulin extraction (Mari et al. 2002; 
Pacini and Mari 2003; Polonsky et al. 1986; Watanabe et al. 1989).  
Thus, a PD feedback-control model is used to precisely estimate the insulin secretion as a 
function of the changes in glucose concentration when plasma C-peptide data unaccounted. 
Consequently, the proposed control model would stimulate the insulin secretion while the PD 
control gains would segregate the possible causes of the metabolic dysfunction and its effects 
(i.e. incretin effects and/or IR). 
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6.2 Physiological models 
6.2.1 Dynamics Insulin Sensitivity and Secretion Test (DISST) Model 
The Dynamic Insulin Sensitivity and Secretion Test (DISST) provides quantitative measures of 
both SI and UN (Lotz et al. 2010; McAuley et al. 2011; McAuley et al. 2007).  The dynamic 
DISST test is similar to the insulin modified IVGTT which uses an alternative modelling 
approach and a higher intensity test.  The DISST SI value is highly correlated to the EIC 
(R=0.81) (Lotz 2007; McAuley et al. 2011), and the test can contrast insulin secretion 
characteristics across patient groups with different levels of IR (McAuley et al. 2011). The 
DISST model consists: 
 ̇   (     )      
  
  
  6.1 
 ̇            6.2 
 ̇         
 
     
 
  
  
(   )  
   
  
 (    )
  
  
  6.3 
 ̇   (   
  
  
)  
  
  
   6.4 
 ̇     (    )    (       )  
  
  
  6.5 
 
Table 6.1-6.2 indicate the nomenclatures that define DISST model, a-priori exogenous input and 
the population parameters used in DISST model. 
Table 6.1 Nomenclatures of DISST model. 
Variable Value Unit Description 
C stimulated mU.L
-1 
Plasma  C-peptide concentration 
Y stimulated mU.L
-1 
Interstitial C-peptide concentration 
UN stimulated mU.min
-1 
Endogenous insulin secretion rate 
I stimulated mU.L
-1 
Plasma insulin concentration 
Q stimulated mU.L
-1 
Interstitial insulin concentration 
G stimulated mmol.L
-1 
Blood glucose concentration 
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Table 6.2 The exogenous input and the population parameters used in DISST model. 
Variable Value Unit Description 
Gb a-priori mmol.L
-1 
Basal blood glucose concentration 
Qb a-priori mU.L
-1 
Basal interstitial insulin concentration 
k1, k2, k3 a-priori min
-1 
C-peptide transport rates 
Vg a-priori L Glucose distribution volume 
Vp a-priori L Plasma insulin distribution volume 
Vq a-priori L Interstitial insulin distribution volume 
nK a-priori min
-1 
Renal insulin clearance rate 
nL a-priori min
-1 
Hepatic insulin clearance rate 
xL a-priori 1 Fractional first-pass hepatic insulin extraction 
nI a-priori min
-1 
Plasma-interstitial diffusion rate 
nC a-priori min
-1 
Interstitial insulin degradation rate 
Uex a-priori mU.min
-1 
Exogenous insulin input rate 
Pt stimulated mmol.min
-1 
Exogenous glucose input rate 
pg 0.004 min
-1 
Non-insulin mediated glucose disposal rate 
αI 0.0017 L.mU
-1 
Hepatic insulin clearance saturation parameter 
6.2.2 Stomach and gut model 
The additional stomach and gut model is defined by Equation 6.6 to 6.8. The proposed model is 
simplified from a system model of oral glucose absorption (Lin et al. 2011). The steady 
exogenous glucose input rate (Pt) in Equation 6.5 is replaced with the term in Equation 6.8. P is 
the glucose appearance rate in bloodstream after oral glucose ingestion in stomach and gut. It is 
only applied in OGTT responses.  
 ̇           6.6 
 ̇              6.7 
     (         ) 6.8 
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The nomenclature defining the two compartment stomach and gut are shown in Table 6.3 with 
constant population parameters. 
Table 6.3 Nomenclature of stomach and gut model. 
Variable Value Unit Description 
P1 stimulated mmol
 
Glucose appearance in stomach 
P2 stimulated mmol Glucose appearance in gut 
P stimulated mmol.min
-1 
Glucose appearance in bloodstream from oral meal 
Pmax 6.11 mmol.min
-1 
Maximum glucose flux from gut to plasma 
d1 0.1 min
-1 
Glucose transport rate from stomach to gut 
d2 0.0347 min
-1 
Glucose transport rate from gut to plasma 
D 75 g Oral glucose load 
The parameter values (d1 and d2) are reported to be the maximum rate of glucose appearance in 
both compartments.  
6.2.3 PD feedback-control model of Uen 
To reach glucose homeostasis, the body uses closed-loop, feedback-control system that defines 
the rate of insulin secretion in response to glucose and insulin concentrations. The proportional-
derivative (PD) controller defines participant-specific Uen profiles that are function of increasing 
glucose (derivative control,   ) and glucose above basal (proportional control,   ). 
The PD feedback-control model of Uen used in estimating the insulin secretion characteristics is 
defined: 
         (    ) (    )     ̇ ( )̇   6.9 
where: Uen is a controlled model of insulin secretion (mU.min
-1
); Ub is basal insulin (mU.min
-1
); 
   and    are the proportional and derivative gains (mU.L.mmol
-1
.min
-1
) and (mU.L.mmol
-1
); 
 ( ) is a Heaviside function that renders the coefficients of    and    equal to zero if the 
argument ( ) is negative. 
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6.3 Hypothesis 
The Uen control model consists of proportional and derivative (PD) controller gains. The 
proportional controller gain (  ) exhibits the static and steady-state change of glucose 
concentrations while the derivative controller gain (  ) signifies the dynamic change of glucose 
concentrations over time. It is hypothesised that the dynamic of Uen response is dominated by    
as the magnitude of   >  . Thus, high resolution and precision of measured data are important 
in the Uen control model as    is particularly sensitive to assay error, and thus may lead to 
indistinct controller gains.  
The incretin effects may potentially be segregated by comparing Uen control model responses 
between OGTT (oral glucose consumption) and DISST (IV glucose bolus) cohorts. A study by 
Bergman et al. (2003) showed a 26% higher insulin requirement to maintain normoglycaemia for 
the same amount of food consumption in patients who consumed parenteral nutrition compared 
with those who had enteral feeding. Thus, the incretin effects may be elucidated by comparing 
   
   
 across DISST and OGTT responses. It is assumed that incretin effects occurred when 
   
   
 
OGTT > 
   
   
 DISST. 
6.4 Subjects and Methods 
6.4.1 Participants 
Fifty participants with varying degrees of glucose tolerance were recruited as part of the DISST 
validation trial (McAuley et al. 2011). These participants also underwent the euglycaemic clamp 
(EIC) (DeFronzo et al. 1979), the 4-sample oral glucose tolerance test (OGTT) and DISST 
within 8 days with at least one day between tests (Lotz 2007). Tests were given in random order 
based on their order of recruitment such that each of the six possible combinations was equally 
represented. The main outcome of this prior study by Lotz (2007) was to obtain insulin 
sensitivity metrics derived from the DISST, EIC and OGTT data.  
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On the morning of their first, basic metrics in calculating their BMI (weight, height, age, gender) 
was recorded. They were also required to complete a brief questionnaire concerning family 
history of type 2 diabetes mellitus and personal medical history. 
These 50 participants were passively recruited via flyers and newspaper advertisements from 
Christchurch region of New Zealand in accordance with the conditions of the approved ethical 
consent. The participants were categorised in six subgroups to ensure the study cohort 
represented wider population. The six subgroups were defined as five lean males (BMI<25), five 
lean females, ten overweight males (BMI>25, BMI<30), ten overweight females, ten obese 
males (BMI>30), and ten obese females.  
For simplicity, three subgroups were re-constructed and defined: 
1. 10 lean participants (BMI<25); [5 males, 5 females] 
2. 20 overweight participants (BMI>25, BMI<30); [10 males, 10 females] 
3. 20 obese participants (BMI>30); [10 males, 10 females] 
 
The cohort details were summarised and presented in Table 6.4 and Table 6.5. 
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Table 6.4 Participant details summary from the OGTT/DISST validation study. They were categorised in 
three groups (Lean, Overweight and Obese).   
Lean  
participant 
Gender 
(F/M) 
Age 
(yrs) 
Weight 
(kg) 
BMI 
(kg.m
-2
) 
Fasting 
glucose 
(mmol.L
-1
) 
Fasting insulin 
(mU.L
-1
) 
NGT 
IGT* 
T2DM* 
Q1 
Q2 
Q3 
5 F 
5 M 
25 
28 
30 
59 
63 
72 
20 
22 
23 
4.1 
4.3 
4.4 
2.6 
3.8 
5.2 
10 NGT 
Overweight 
Participant 
Gender 
(F/M) 
Age 
(yrs) 
Weight 
(kg) 
BMI 
(kg.m
-2
) 
Fasting 
glucose 
(mmol.L
-1
) 
Fasting insulin 
(mU.L
-1
) 
NGT 
IGT* 
T2DM* 
Q1 
Q2 
Q3 
10 F 
10 M 
29 
43 
50 
70 
84 
87 
26 
28 
29 
4.2 
4.5 
4.8 
4.8 
7.4 
9.6 
18 NGT 
2 IGT 
Obese 
Participant 
Gender 
(F/M) 
Age 
(yrs) 
Weight 
(kg) 
BMI 
(kg.m
-2
) 
Fasting 
glucose 
(mmol.L
-1
) 
Fasting insulin 
(mU.L
-1
) 
NGT 
IGT* 
T2DM* 
Q1 
Q2 
Q3 
10 F 
10 M 
37 
44 
53 
89 
106 
118 
32 
35 
39 
4.5 
4.8 
5.0 
8.0 
10.4 
22.7 
17 NGT 
2 IGT 
1 T2DM 
*based on 2hr OGTT glucose criteria of the ADA (2006). 
Table 6.5 Overall cohort characteristics from OGTT/DISST validation study. 
Overall 
Participant 
Gender 
(F/M) 
Age 
(yrs) 
Weight 
(kg) 
BMI 
(kg.m
-2
) 
Fasting 
glucose 
(mmol.L
-1
) 
Fasting insulin 
(mU.L
-1
) 
NGT 
IGT* 
T2DM* 
Q1 
Q2 
Q3 
25 F 
25 M 
29 
41 
50 
72 
85 
99 
26 
29 
33 
4.3 
4.6 
4.8 
4.6 
8.0 
11.2 
45 NGT 
4 IGT 
1 T2DM 
*based on 2hr OGTT glucose criteria of the ADA (2006). 
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Due to inconsistency and assay error in two participants (1 NGT, 1 IGT) during OGTT 
assessment, only 48 participants were considered in this analysis.  
6.4.2 Insulin sensitivity tests 
6.4.2.1 DISST protocol 
Participants had a cannula inserted into the antecubital fossa (large vein in the inner elbow) for 
blood sampling and bolus administration. A three-way tap was connected to the cannula to 
facilitate the extraction of ‗dead-space‘ during sampling and enable flushing of boluses. Blood 
samples were drawn at t=0, 10, 15, 25 and 35 minutes and glucose, insulin and C-peptide 
concentraions were measured on these samples. A 10g bolus glucose (50% dextrose) was given 
at t=5 minutes and 1U of Actrapid insulin was administered immediately after the t=15 minutes 
sample. Participants were required to remain at the clinic for 30 minutes after the test and were 
provided with a small meal or snack. Due to the occasional difficulty in maintaining a free 
flowing cannula, some blood samples were not taken precisely at the time defined by the 
protocol. The consistency of the samples measurement in a dynamic test is critical to the 
accuracy of the resultant metrics. Thus, a timer devise was used to record the actual times of the 
samples and boluses administered to the participants. 
A purpose built sample timing program was installed on a palm-held computer with a purpose-
built software package installed. The program displayed a large countdown timer for each 
scheduled sample. The trained clinician recorded the actual times (up to 1-second resolution) that 
the samples and boluses were performed by pressing a single button. The software was encoded 
in visual basic studio (.NET).  
6.4.2.2 OGTT protocol 
Participants recruited in this study had an OGTT for assessment diabetes status. Participants 
were given a standard lightly carbonated 75g glucose drink, immediately after a fasting blood 
sample. A cannula was placed in the antecubital fossa to enable blood samples. Further blood 
samples were collected at t=30, 60 and 120 minutes. Glucose and insulin concentrations were 
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measured in each sample. All samples were assayed for glucose at the bedside, spun and frozen 
for later insulin assays. 
Current diabetes diagnosis criteria from ADA (2006b) includes either 120-minute glucose assay 
greater than 11.1 mmol.L
-1
, fasting glucose>7.0 mmol.L
-1
 (126 mg.dL
-1
) or/and HbA1c (glycated 
haemoglobin, which identifies average plasma glucose concentration)>7% (53 mmols.mol
-1
) can 
be used to diagnose diabetes. This must be confirmed on a second test on another day with 120-
minute glucose values from the OGTT are between G≥6.1 and G<7.0 mmol.L-1 (≥110 and <126 
mg.dL
-1
), which indicates impaired glucose tolerance. 
6.4.2.3 Assay techniques 
Glucose assays were analyzed using YSI 2300 stat plus Glucose and L-Lactate analyzer using 
whole blood. These were converted to plasma glucose, using Equation 6.9. Samples for insulin 
and C-peptide were immediately separated. Then the samples were frozen. Measurements of 
insulin were undertaken by the Endolab, Canterbury Health Laboratories using Roche Elecsys® 
after PEG precipitation of immunoglobulins (Roche Diagnostics, Mannheim, Germany). All C-
peptide measurements were also undertaken by Endolab, Canterbury Health Laboratories using 
the Roche Elecsys® method. Serum cholesterol and triglycerides were measured enzymatically 
with Roche kits and HDL was measured in the supernatant after precipitation of apolipoprotein B 
containing lipoproteins with phosphotungstate/magnesium chloride solution (Assmann et al. 
1983). 
        
                  
(          )             ( )
 6.10 
  
6.4.3 Parameter Identification  
The analysis was conducted with the DISST methodology defined in study by McAuley et al. 
(2011). Initially, the prior study results was used to define participant-specific Ub, nL, xL, SI, and 
Vg parameter values as well as glucose and Uen profiles for DISST response using experimental 
data (McAuley et al. 2011) with Equation 6.1 to 6.5 and iterative integral method (IIM) 
(Docherty et al. 2012). 
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The a-priori parameter identification of participant-specific Ub, nL, xL, SI, and Vg  
The C-peptide model was de-convoluted using linear interpolation of the plasma C-peptide data 
(Cinterp) (Lotz et al. 2010). Equation 6.2 can thus be solved analytically for Y(t). 
      ∫         
   (   )  
 
 
 6.2a 
 
This term was incorporated into the integral formulation of Equation 6.1: 
            ∫ ∫        
 
 
    (   )     (     )
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 6.1a 
 
Equation 6.1a was rearranged for the participant‘s endogenous insulin secretion response to the 
test stimulus, UN. 
  (  )    (  )
  
             ∫ ∫        
 
 
    (   )     (     )
  
  
∫    
  
  
 
 6.1b 
Thus, UN was defined using Equation 6.1b at a 1-minute resolution between t=0 and t=end. 
The participant‘s insulin concentration response to the test stimulus was defined using the 
physiological model of Equation 6.3 and 6.4, the a-priori parameter values for each participant 
were discussed in detail in DISST validation study (Lotz 2007; McAuley et al. 2011) using Van 
Cauter‘s mathematical formula (Van Cauter et al. 1992) and UN profile identified with Equation 
6.1b. 
To estimate minute-wise insulin profiles, insulin data was linearly interpolated between t=0 and 
end at the end of the test. The corresponding interstitial insulin concentration (Q) was identified 
using the analytical solution of Equation 6.4 with assumption of          (Pretty 2012). 
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   ) 6.4a 
where i = the test sample time. 
Thus, profiles for both plasma and interstitial insulin responses to the test stimulus were defined. 
The IIM (Docherty et al. 2012) was used to identify participant-specific hepatic clearance (nL) 
and extraction (xL) values. The integral formulation of Equation 6.3 was separated into the 
coefficients of the known and unknown parameters: 
  ∫
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6.3a 
 
These coefficients were identified corresponds to the sample times of the test that began from 
t0=0 to t=t1, t2, ... , tend. This approach allowed the generation of a matrix equation in terms of nL 
and xL to be formed: 
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  6.3b 
Thus, nL and xL were able to be constrained as necessary and identified using linear least square 
methods. The plasma and interstitial insulin concentration profiles were re-simulated using the 
DISST physiological model (Equations 6.3 and 6.4) with the identified hepatic clearance and 
extraction parameters. 
The physiological stimulation of Q was then used with the glucose data and the IIM (Docherty et 
al. 2012) to identify participant-specific values for SI and Vg. A linear interpolation was then 
used as an estimate of the glucose response to the test stimulus. The integral formulation of 
Equation 6.5 was rearranged and separated into the coefficients of the known and unknown 
parameters. The coefficients of the glucose model parameters were evaluated over the sample 
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times from t0=0 to t=t1, t2, ... , tend, at the end of the test. These periods were chosen to minimise 
the fitting error and the variability of the identified insulin sensitivity (Docherty et al. 2011). 
Thus, a second matrix formulation was defined in terms of SI and Vg. 
  ∫ (       )  
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∫     
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 6.5a 
A matrix formulation was then defined in terms of SI and Vg in Equation 6.5b: 
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  6.5b 
 
Bounds were placed on the value of Vg to reduce the effect that incomplete mixing might have on 
the sensitivity term. The values of Vg are limited to within 12 to 25% of the participant‘s 
bodyweight, per published data (Lotz 2007; Lotz et al. 2010; McAuley et al. 2011). Evaluation 
of Equation 6.5b yielded participant-specific SI and Vg. 
The same methodology with participant-specific (Ub, nL, xL and VG) defined in prior study 
(McAuley et al. 2011) used to identify SI and P for OGTT response. P is determined using 
Equation 6.8 from stomach and gut model.  
The   and   controller gains identification 
Then, Equation 6.3 and 6.9 were combined to individually identify    and    in Equation 6.11. 
The Equation 6.11 was then separated into the known (X) and unknown parameters (   and   ).  
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6.11 
The physiological stimulation of Q obtained in Equation 6.4a was then applied to Equation 6.11 
using the a-priori parameters (Ub, nL, xL, SI, and Vg) of DISST and measured insulin data from 
DISST and OGTT (Uex = 0) tests. The known parameters and data are gathered, that can be 
defined as X in Equation 6.11a: 
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Lastly, Equations 6.11(a-e) was then used with insulin and glucose data from DISST and OGTT 
tests to identify    and    using IIM, which generates the linear least square equations (similar 
to nL and xL parameter identification process in Equation 6.3a and 6.3b ): 
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  6.11e 
 
where: the coefficients of the    and    model parameters were evaluated over the sample times 
from t0=0 to t=t1, t2, ... , tend, at the end of the test. RR implies a ratio between    and    and GG 
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defines the magnitude of the penalty for deviation from the defined ratio (relative to the least 
squares fit). 
The    and    values were identified in Equation 6.11(e) for each test response with RR = 30 
implying that         and GG is 1 giving a relatively weak weighting to this ratio. Model 
residuals and interpretation of population trends were used to assess the performance of this PD 
control model. 
The plasma and interstitial insulin concentration profiles were re-simulated using physiological 
model (Equation 6.3 and 6.4) with the identified    and    values for both DISST and OGTT 
assessments. Also, Uen control model response in Equation 6.9 was stimulated for comparison 
between NGT and IGT/T2DM. 
6.4.4 Statistical analysis 
The performance of this Uen (PD) control model was assessed via model residuals and 
interpretation of population trends between the DISST and OGTT model. Insulin model residuals 
(  ) are defined with Equation 6.12 
    
 
 
∑(         ( )         ( ))   6.12 
where blood samples were collected at t=t0,t1,t2,...,tn for the measurement of plasma glucose and 
insulin respectively. The mean residual for G was computed similarly. 
The Kolmogorov-Smirnov (K-S test) is sensitive to differences in both location and shape of the 
empirical cumulative distribution functions of the two distributions. Thus, the K-S test was used 
to distinguish difference between DISST and OGTT parameter in distributions. All statistical 
analysis computed in this chapter using MATLAB (R2011b) (MathWork, Inc., Natick). 
6.5 Results and discussion 
The responses of the Uen control model were used to investigate and compare the dynamics of 
the metabolic effects for DISST and OGTT responses. Both controller gains of    and    
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engaged with glucose concentrations to accurately stimulate the true insulin secretion after 
glucose ingestion.      
6.5.1 Controller gains (  ) and (  ) 
The relationship between Uen control model response and glucose concentration are defined as 
the sum of two controller gains.    represents the relationship between insulin secretion and 
glucose concentration over steady state concentration.    represents the dependence of insulin 
secretion on the rate of change in glucose concentration. This rate sensitivity effectively 
anticipates glucose concentrations rise over time.  
Linear correlations in Figure 6.1(A) are observed between controller gains of    and    
clarified that the PD control model is well-functioned in estimating Uen concentration. The 
control model summarised the linear correlation between controller gains and Uen control model 
response. Figure 6.1(A) shows that the DISST‘s    and    has correlation of R=1 and R=0.96 
for OGTT. Additionally, Figure 6.1(B) shows    of the OGTT response is correlated by R=0.42 
with    of DISST response while Figure 6.1(C) indicates that    of OGTT response is 
correlated by R=0.49 with    of DISST response.  
Figure 6.1 (A) Distribution of    and    for all participants underwent DISST and OGTT. (B)    (C) 
   controller gains comparison between OGTT and DISST responses. 
The identified controller gains of    and    for both responses (DISST and OGTT) are shown 
in Table 6.6 and Figure 6.1. Figure 6.1(B and C) shows that    and    controller gains for the 
A 
B C 
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OGTT response are only marginally greater than the DISST response. The median    and    of 
OGTT population response is increased by 10% and 20% compared to DISST, respectively, as in 
Table 6.6. The magnitude of    are higher than    due to the ratio constraint.    portrays the 
magnitude of insulin secretion (β-cell function) with the changes of glucose fluxes. After oral/IV 
ingestion, increased glucose fluxes cause an increased rate of endogenous insulin secretion. 
While the    controller gain only traces the absolute glucose concentration above the basal 
(minimum) level. Thus,    defines the dominant behaviour in producing insulin in response to 
the glucose fluxes after glucose ingestion. Overall, results clearly show that the Uen control 
model response is led predominantly by    controller gain as this gain parameter signifies the 
sensitivity of the model control due to changes in glucose concentration over time.  
Table 6.6 Identified controller gains using IIM for both DISST and OGTT responses. 
Identified parameters 
using IIM 
Median [IQR] 
p-value 
DISST OGTT 
    
(mU.L.mmol
-1
) 
252.36 
[181.90,339.53] 
268.80 
[189.42,467.03] 
0.014 
    
(mU.L.mmol
-1
.min
-1
) 
8.43 
 [6.07,11.32] 
10.50  
[7.06,16.78] 
0.003 
  
  
 (min) 
29.96  
[29.87,30.04] 
28.4 
[25.2,29.5] 
<0.0001 
 
The most critical parameter in influencing observation of incretin effect is the proportional ratio 
between    and    controller gains. However, it was found that the median 
  
  
 of OGTT and 
DISST responses were approximately the same (Table 6.6). This indicates that incretin effects 
were unobservable during oral glucose ingestion. Due to limited low resolution data of glucose 
and unmeasurable of GLP-1 and/or GIP concentrations in the OGTT assays it is suggested that 
the incretin effects can hardly be observed as the DISST model unable to capture the dynamics 
(via model fits) of this metabolic effects. OGTT consists only four glucose data points over 120-
minute assessment which is insufficient to segregate the incretin effects as Uen control model 
response integrated with more complicated dynamics to modulate the true physiological Uen as 
glucose concentration changes over time. Furthermore, the OGTT response involves another 
dynamic input to the PK-PD models as oral glucose ingestion requires stomach and gut pathway 
for glucose appearance in bloodstream. The variable rate of glucose appearance during the 
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OGTT is difficult to model and requires further glucose measurements through gut.  Thus, high 
resolution measurements of glucose concentrations and C-peptide measurements are essential to 
investigate the complexity of incretin effects in OGTT response. 
An additional stomach and gut model assumption was introduced to define the unknown glucose 
appearance rate in OGTT response. Consequently, the glucose-insulin PD model stimulated slow 
and steady-state rate of glucose appearance (P) after glucose absorption in gut (P2) and the rate 
of glucose appearance in blood (d2) and SI were identified using IIM.  This stomach and gut 
model assumption was simplified from a nutrition model proposed by Lin et al. (2011). Model 
parameter were initially set to d1=0.1 (min
-1
), d2=0.0347 (min
-1
) (Lin et al. 2011) before the 
parameter identification process of SI. The decay of glucose appearance rate is set to be constant 
0.0347 min
-1 
(the half-life of glucose appearance in bloodstream is assumed to be 20 minutes). 
Thus, the Uen response amongst OGTT tests will either over or under-estimate the ‗real‘ insulin 
secretion due to difficulty in estimating individual P and d2 values which linked to the measured 
glucose. 
The distribution of  
   
   
  OGTT and  
   
   
 DISST responses as a function of SI is illustrated in 
Figure 6.2. The 
   
   
 DISST responses are tightly bound to 30 as the model assumption implies 
that         despite the modest gain applied to the model. Thus, the Uen responses of DISST 
reflect the true physiological insulin secretion due to the changes in glucose concentrations. 
However, the 
   
   
 OGTT responses are scattered due to the ‗unmeasured‘ dynamics of the model 
assumption (i.e glucose appearance) after oral glucose ingestion. Presumably, the performance of 
Uen control model assumption in OGTT response is generally lower compared to DISST. OGTT 
assessment requires high resolution glucose data to perform the Uen control model in PK-PD 
model to capture the incretin effects after oral glucose ingestion.  
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Figure 6.2 Distribution of  
   
   
  OGTT and  
   
   
 DISST responses as a function of SI. 
The modeled SI is directly correlated to the response of interstitial insulin and glucose 
concentrations. In DISST and OGTT studies, there were four subjects diagnosed with 
IGT/T2DM based on the OGTT (ADA, 2006). IR is defined as abnormalities of SI or insulin 
responsiveness (Kolterman et al. 1981). In particular, IR participants of the OGTT relied more 
heavily on the second phase insulin secretory response to glucose. This is supported by the 
literatures (Fehse et al. 2005; Garvey et al. 1985; Luzi and DeFronzo 1989). 
6.5.2 Evaluation on Uen control model 
The proposed Uen control model is designed to capture the relationship between Uen 
concentrations and controller gains of (   and   ) which define the physiology of pancreatic β-
cell glucose sensitivity (i.e. insulin secretion in response to changes in glucose concentrations). 
Due to the added model assumption of gut and stomach model in Equations 6.6–6.7 the glucose-
insulin PD model has a slow rate of glucose appearance in blood after glucose passed through the 
gut and stomach compartments. This affects the modeled SI. Therefore, Uen control model 
exhibited slow and steady Uen response amongst OGTT cohort compared to DISST cohort. The 
Uen response amongst DISST subjects was abrupt dynamic in counter-regulation the 
administration of IV glucose infusion at t=5 minutes after test commenced.  Thus, the robustness 
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of the Uen control model was verified within these two different tests and the control model 
performance was reliable despite the limitation of measured data. 
By specifically modelling Uen response of NGT, IGT and T2DM participants would be 
segregated the difference in insulin secretion referring to the participant‘s IR levels. Figure 6.3 
illustrated the difference in Uen control model response of DISST and OGTT tests with three 
different IR levels. 
Figure 6.3 Difference of modeled Uen between NGT (A) lean, IGT (B) obese and T2DM (C) obese 
participants underwent DISST and OGTT. 
The Uen responses and modeled SI that correspond to controller gains (   and   ) were 
evaluated for comparison using the same individuals by the OGTT and DISST assessments. It 
was found that the participant who had diabetes (T2DM) in Figure 6.3(C) had a higher insulin 
secretion than those with normal glucose tolerance (Figure 6.3(A)). In Figure 6.3(C), Uen 
response was greatly increased due to the reduced SI of the T2DM participant. IR is the main 
contributor of increased demand on Uen secretion which causes hyperinsulinemia. Additionally, 
high insulin secretion in the obese participants with IGT/T2DM is also caused by failure in β-cell 
function to settle to basal insulin secretion after glucose ingestion.   
Uen response time to the maximum estimated Uen rate amongst the OGTT cohort is variable 
between NGT and IGT/T2DM. The Uen(max) response time for IGT/T2DM participants‘s are 
C B A 
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approximately 30-50 minutes as in Figure 6.3(B and C). In contrast, the DISST average peak Uen 
response required only 7 minutes to reach the maximum estimated rate of insulin secretion. This 
explained the fast and quick action of Uen control model in reaching normoglycaemia state 
approximately 30-40 minutes after IV glucose consumption amongst DISST subjects. However, 
OGTT subjects attained longer period in reaching normoglycaemia (≈ 80 minutes) as the model 
control generated steady and slower Uen rate until it settled to baseline insulin secretion rate as in 
Figure 6.3(A).  
The Uen control model responses of DISST with C-peptide data, DISST and OGTT were drawn 
for comparison in Table 6.7. Two Uen responses of first phase the total insulin secretion were 
calculated for each assay according to participant‘s IR states. 
Table 6.7 Insulin secretion of first phase area under the curve, (U1), and total area under the curve, 
(UTotal), of modeled Uen comparison between DISST with C-peptide, DISST and OGTT responses. 
Assay  
U1 (mU) 
Median [IQR] 
UTotal (mU) 
Median [IQR] 
DISST with  
C-peptide data 
NGT 571 [465,739] 2590 [1972,3391] 
IGT/T2DM 609 [515,806] 3668 [2686,4720] 
Total 585 [465,739] 2623 [2019,3412] 
DISST 
NGT 936 [742,1234] 2735 [2064,3569] 
IGT/T2DM 1139 [841,1283] 3621 [2751,4213] 
Total 962 [742,1240] 2813 [2120,3626] 
OGTT 
NGT 2659 [1878,3746] 7220 [5262,10107] 
IGT/T2DM 3275 [2705,4791] 15381 [11458,21213] 
Total 2682 [1982,3746] 8038 [5377,11735] 
 
The simplest method in assessing insulin secretion from OGTT data is the calculation of the 
measured insulin concentration area under the curve (AUC), over the whole test. AUC gives an 
idea of the amount of insulin that acts on the tissues, but lacks any information on the dynamics 
of the hormone in terms of secretion and clearance. To validate the Uen control model responses 
with the DISST study (with C-peptide data) by McAuley et al. (2011), Table 6.7 was constructed 
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to portray the estimated AUC between DISST and OGTT. The first phase (U1) is defined by area 
under the curve at the first peak and the total secretion (UTotal) is the total area under the curve of 
insulin secretion. Both values were determined as population median [IQR].  Overall, the OGTT 
cohort delivered the highest U1 and UTotal. The DISST response has approximately the same 
amount of UTotal compared to DISST with C-peptide data. The DISST model with C-peptide data 
estimated Uen concentration directly from plasma C-peptide PK model to estimate Uen response. 
6.5.3 Glucose and Insulin pharmacodynamics/kinetics model responses 
DISST protocol was designed to improve upon the intravenous glucose tolearance test (IVGTT) 
protocol. The DISST protocol was comparatively low-dose insulin IV boluses and has shortened 
duration. Thus, to define insulin PK and glucose-insulin PD models of DISST protocol, the 
DISST model (Docherty et al. 2010; Lotz 2007) was designed with modification of the minimal 
model (Bergman et al. 1979) and the C-peptide PK model of Eaton et al. (1980). 
Three participants model fit examples are shown in Figures 6.4-6.6 and verify that Uen control 
model captured different responses based on participant health (IR levels). The DISST validation 
study successfully identified participant-specific parameters (Ub, nL, xL, SI, Vg) by modelling 
insulin PK and glucose-insulin PD models. This adaptation of this Uen control model in DISST 
model elucidates the relationship insulin secretion in response to changes in glucose 
concentration.  
In general, Tables 6.8–6.10 show comparison between DISST and OGTT challenges (NGT, IGT 
and T2DM participants) of modeled SI, 
  
  
 controller gain response and total insulin secretion 
corresponds to the model response.
 
86 
 
The model responses of 21 years old lean (BMI=19 kg.m
-2
), NGT participant are illustrated in 
Figure 6.4. 
 
Figure 6.4 Model responses of a NGT participant underwent DISST; (A) glucose and (B) plasma and 
interstitial insulin, and OGTT; (C) glucose and (D) plasma and interstitial insulin. 
Table 6.8 Comparison of identified parameters based on model responses of a NGT participant shown in 
Figure 6.4. 
NGT participant SI 
(L.mU
-1
.min
-1
) 
  
  
 (min
-1
) 
UT 
(mU) 
DISST 0.0010 30.04 1479 
OGTT 0.0014 29.54 4019 
 
It can be concluded that the PD control model was successfully applicable in DISST models 
particularly in this participant as good model fits with minimum residual are observed in Figure 
6.4. Although modeled I and Q for this participant (Figure 6.4(A) and (B)) slightly drifted from 
measured I in the OGTT response, the model fit still delivered good residual with limited 
measured data. As 
  
  
 controller gain response for the OGTT was equally the same as 
  
  
 for the 
DISST, it may elucidate that the incretin effects is not significant when insulin is produced 
during glucose ingestion for the OGTT response. Thus, further investigation with high resolution 
A B 
C D 
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of glucose and C-peptide measurements is required to observe the incretin effects in OGTT 
responses.  
Model responses of an IGT participant who underwent OGTT and DISST challenges are 
illustrated in Figure 6.5. This participant is borderline obese with a BMI≈30 kg.m-2.  
Figure 6.5 Model responses of an IGT participant underwent DISST; (A) glucose and (B) plasma and 
interstitial insulin, and OGTT; (C) glucose and (D) plasma and interstitial insulin. 
Table 6.9 Comparison of identified parameters based on model responses of an IGT participant shown in 
Figure 6.5. 
IGT participant SI 
(L.mU
-1
.min
-1
) 
  
  
 (min
-1
) 
UT 
(mU) 
DISST 0.0008 29.93 3108 
OGTT 0.0001 22.84 12921 
 
The modeled G, I and Q model responses to the OGTT were poorly fitted. The variable rate of 
glucose appearance in bloodstream after glucose ingestion is difficult to model given only four 
available glucose measurements. Also, IR is compensated by increased insulin secretion (Larson 
& Ahren, 1998) which is illustrated in this IGT participant‘s Uen response. However, the total Uen 
responses of OGTT (Table 6.7 and 6.9) amongst IGT/T2DM participants were considerably 
over-estimated from true Uen obtained from DISST study with C-peptide data (McAuley et al. 
A B 
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2011). Thus, DISST model with OGTT response could not fully capture the dynamics and its 
effects within PK-PD models, thus reducing the parameter identifiability of SI. Thus, the PD 
control model performance in OGTT responses is comparatively low via the proportional ratio of 
controller gains 
  
  
 which causes high residual in model fit of I. However, this IGT participant 
delivered good model responses in term of controller gains 
  
  
 ≈ 30 with DISST response as 
expected.  
A T2DM participant‘s model responses underwent DISST and OGTT challenges are illustrated 
in Figure 6.6. This participant is obese with a BMI≈42 kg.m-2. 
Figure 6.6 Model responses of a T2DM participant underwent DISST; (A) glucose and (B) plasma and 
interstitial insulin, and OGTT; (C) glucose and (D) plasma and interstitial insulin. 
Table 6.10 Comparison of identified parameters based on model responses of a T2DM shown in Figure 
6.6. 
T2DM participant SI 
(L.mU
-1
.min
-1
) 
  
  
 (min
-1
) 
UT 
(mU) 
DISST 0.00013 29.54 4133 
OGTT ≈0 11.64 17841 
As a participant‘s IR level increases (especially during T2DM), the Uen model response is also 
increased. This is due to hyperinsulinaemia occurred in T2DM which excessive insulin secretion 
A B 
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apart from inability of glucose uptake by insulin binding receptor as target tissues fails to 
respond appropriately to insulin (Ferrannini et al. 1991; Weyer et al. 1999). This causes high 
glucose concentration and failure to settle to basal concentrations after oral/IV glucose. As a 
result, insulin sensitivity decreased. Again, results show that incretin effects are impossible to be 
observed in IGT/T2DM participants as  
  
  
 of these participants is far more less than  
  
  
 of the 
NGT participants. This incretin effect is highly suppressed and not significant due to other 
metabolic dysfunctions and the inability of Uen control model to capture this effect as low 
  
  
 
response is observed (Table 6.10). In this analysis small numbers (N=5) of participants 
associated with IGT/T2DM were identified. Therefore, further investigation with larger cohort of 
IGT/T2DM is required to investigate insulin secretion and incretin effects that affect this 
metabolic dysfunction using this approach.  
6.5.4 Validation and residual 
OGTT is not generally considered a surrogate assessment for SI and is used specifically for the 
diagnosis of type 2 diabetes. It measures the body‘s ability to clear a 75-g glucose load, which 
indirectly computes insulin sensitivity based only on measured glucose concentrations with (if 
any) plasma insulin measurements. The OGTT protocol in this study only measured glucose and 
plasma insulin concentrations. Ideally additional measured C-peptide would further validate the 
participant-specific parameters from DISST validation study using pharmacokinetic model from 
Van Cauter‘s study (1992). Prior studies (Belfiore et al. 2001; Gutt et al. 2000; Matsuda and 
DeFronzo 1999; Soonthornpun et al. 2003; Stumvoll et al. 2000) proposed index of insulin 
sensitivity derived from OGTT with wide range of glucose tolerance and several have validated 
it against EIC (R=0.56, p<0.001) (McAuley et al. 2011). 
Table 6.11 shows the population mean residual of G and I model responses for DISST and 
OGTT challenges. The model response in G for both challenges seemed consistent and accurate 
as the medians of population mean residual were calculated to be 0.06 mmol.L
-1
 (DISST) and -
0.16 mmol.L
-1
 (OGTT). However, the median of population    values was ~40 times the 
difference between the OGTT and DISST model responses.  
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Table 6.11 Population mean residuals (median, [IQR]) of G and I model responses for DISST and OGTT 
challenges. 
Mean residual  
 
Median 
[IQR] 
p-value 
DISST OGTT 
G (mmol.L
-1
) 
0.06 
[0.02,0.12] 
-0.16 
[-0.57,-0.03] 
<0.0001
 
I (mU.L
-1
) 
0.05  
[-0.45,0.43] 
-2.19 
[-6.08,0.48] 
<0.0001 
 
Figure 6.7 Mean residual per-participant between measured G (A) and I (B) data and model responses 
from DISST and OGTT. 
The goodness plasma insulin and interstitial insulin model fit determines the performance of the 
Uen control model. Ambiguous glucose stimulus during the OGTT test causes poor model fits 
with high residual which overall generates variable Uen response. This high response variability 
might hinder the observation of underlying metabolic effects that enhance insulin secretion. The 
fitting error is potentially due to the low resolution of the OGTT glucose measurements. The 
model identifiability issues (Docherty et al. 2011) also limit the accuracy of    controller gain to 
estimate the true Uen response.  
Other factors which contribute to the high residual in I model response is the fairly poor 
estimation of Uen control model based only on the changes in glucose concentration and a-priori 
A 
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parameter estimation of (nL, xL and Ub) from DISST study (McAuley et al. 2011). Due to limited 
data accessibility in identifying five parameters (nL, xL,  ,    and Ub) in plasma insulin PK 
model, three out of these five parameters were assumed from the prior DISST study (McAuley et 
al. 2011). However, a study by Nauck et al. (1986) proved that after oral glucose ingestion, the 
estimated fractional hepatic insulin extraction, xL, to be significantly lower than that during IV 
glucose infusion (63.4-76.5%). Thus, this factor slightly contributes to the overall discrepancy in 
I model response.  
Overall, the Uen control model is generally well developed amongst normal participants, 
particularly in DISST response despite the limited measured data. The incretin effects were not 
significant in OGTT response in comparison to DISST after glucose ingestion. However, rough 
estimation of participant-specific parameters (nL, xL) and the imprecise estimation on endogenous 
insulin secretion baseline concentration (Ub) especially in IGT and T2DM participants in OGTT 
challenge might contribute to bias. Thus, a clear understanding of plasma insulin/interstitial PK 
models and glucose PD model is particularly essential in investigating the incretin effects and 
insulin-glucose interaction. Also, repeatability and variability study with additional measured C-
peptide, GLP-1 and GIP hormones concentration in a large cohort which covering all levels of 
insulin resistance should be conducted to validate the proposed Uen control model. 
6.6 Summary 
The dynamic insulin secretion responses to changes in glucose concentration can be modeled 
using PD feedback-control approach. The new model allows the characterisation of both static 
(basal) and dynamic insulin secretion model responses which define the pancreatic β-cell glucose 
sensitivity parameters. The application of this model to various physiological states associated 
with alterations in insulin secretion and/or kinetics provides novel links into the role of plasma 
insulin/interstitial PK models and glucose-insulin PD model.   
The potential to simultaneously assess β-cell glucose sensitivity during an OGTT adds 
significant value i.e. tracking and evaluating incretin effects amongst normal subject to the 
DISST model with additional gut and stomach model and Uen control model. This will require 
measurements of plasma C-peptide concentration and the use of the independent glucose-insulin 
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PD model and insulin/interstitial PK models (Docherty et al. 2010; Lotz 2007) for glucose-
insulin regulatory mechanism. The proposed Uen control model of insulin secretion and kinetics 
will provide the ability to precisely define the pancreatic β-cell function in relation to insulin 
sensitivity. 
Care must also be applied in adopting simplistic methods as assay errors can lead to 
compensations among parameters and consequently to inaccurate models of pancreatic β-cell 
function defined by    and   . The control model and methods proposed here which enable one 
to obtain a specific observation on both β-cell function and insulin kinetics in a single approach, 
delivered a good compromise between model simplicity and accuracy. 
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Chapter 7. Impact of Haemodialysis on Insulin Sensitivity and 
Insulin Kinetics  
Glucose intolerance and hyperinsulinemia are common in acute renal failure patients (DeFronzo 
et al. 1978; Hartmann et al. 1997; Lebovitz 2001; Mak 2000; Nestler et al. 1988; Reaven 1988). 
Critically ill patients often have renal failure and are normally treated with haemodialysis 
therapy (Basi et al. 2005; Bellomo and Egi 2005). It is process that removes waste products such 
as urea and creatinine from the blood to replace kidney function (Hoste et al. 2003). Other 
dialysis therapies such as, Peritoneal Dialysis, Continuous Arteriovenous Heamofiltration 
(CAVH) or Continuous Arteriovenous Haemodialysis (CAVHD) are also used. However, these 
therapies are slower and require special procedures, which are intermittent or continuous, 
depending on patient condition (Bellomo and Egi 2005; Lauer et al. 1983). More importantly, 
the impact of haemodialysis treatment on the glycaemic behaviour of critically ill patients with 
ARF is still unclear. Given the strong links between glycaemic variability and clinical outcomes 
(Branco et al. 2005; Capes et al. 2000; Van den Berghe et al. 2001) it would be useful to know if 
this common therapy affects metabolic management. The study in this chapter investigates this 
question.  
7.1 Introduction 
Acute renal failure, (ARF) is a common complication among critically ill patients, especially for 
elderly patients with diabetes (Thomas et al. 2007). Approximately 36% of critically ill patients 
are diagnosed with ARF (De Mendonça et al. 2000; Metnitz et al. 2002; Uchino et al. 2005) with 
a significant proportion progressing to chronic renal failure requiring weekly haemodialysis, 
(HD), (Star 1998). Several epidemiological studies have shown an increase in morbidity and 
mortality following the development of ARF (Bentley 2011; Hoste et al. 2003; Mak 2000; 
Metnitz et al. 2002).  
The increasing incidence of critically ill patients with ARF associated with increased insulin 
resistance may be explained by several factors, including a rising incidence of sepsis (Bagshaw 
et al. 2007; Marvin and Morton 2009), major surgery (especially cardiothoracic), nephrotoxic 
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medications, and chronic medical conditions (Hoste et al. 2003). With both uraemia and HD 
treatment, glycaemic control (GC) can be complicated (Mak 2000) as GC can affect insulin 
secretion, insulin clearance, gluconeogenesis (Van den Berghe et al. 2001) and peripheral tissue 
sensitivity of insulin (Shrishrimal et al. 2009). Importantly, HD treatment improves patient 
condition by removing waste and toxin from the blood. However, clinical studies have also 
shown that HD treatment clears plasma insulin through increased absorption (Abe et al. 2007; 
Kobayashi et al. 2000; Stenvinkel et al. 1992), which will affect glycaemic management and 
control. Overall, the effect of renal failure on metabolic kinetics in critically ill patients is 
unknown. These unknown effects have the potential to complicate metabolic management and 
treatment. 
In particular, insulin resistance is persistent in many ARF patients (Mak 1995; Marvin and 
Morton 2009). Hence, these patients are at risk of developing hyperglycaemia (Mak 2000) with 
its associated negative outcomes (Krinsley 2003; Weekers et al. 2003). The mechanism of 
glucose intolerance in ARF patients is ambiguous (Hampers et al. 1966). DeFronzo et al. (1981) 
and Mak (1994) showed that insulin resistance among ARF patients improved during a 10 week 
course of HD treatment. However, the net effect of HD treatment on glycaemic regulation and 
insulin sensitivity (SI) in a critically ill cohort is still unknown. 
This analysis uses dense clinical data and a model-based analysis to investigate changes in a 
clinically validated, model-based SI metric at HD transitions in a cohort of critically ill patients. 
We hypothesized that the observed SI would decrease during HD due to enhanced insulin 
clearance compared to the model, and would be recaptured again when HD is stopped. These 
changes in modeled SI would thus offer a unique observation on insulin kinetics and action in 
this population of critically ill patients with ARF that would better inform metabolic care.   
7.2 Subjects and Methods 
7.2.1 Patient cohort 
Retrospective blood glucose (G) measurements, nutrition administration rates (P), and insulin 
delivery (Uex) data for this study were obtained from the Specialized Relative Insulin Nutrition 
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Titration (SPRINT) study of 371 critically ill patients that required glycaemic control (Chase et 
al., 2008). A total of 51 of 371 patients (14%) had acute renal failure (ARF) treated with HD. 
The exogenous insulin and nutrition given to these patients were optimized to maximise blood 
glucose time in the range between 4.0-7.0 mmol.L
-1
, minimising hyperglycaemia, via patient-
specific nutrition and insulin administration (Chase et al. 2008; Lonergan et al. 2006).  
The 51 ARF patients were treated with haemodialysis (HD) with polysulfone (PS) dialyzer 
membrane (APS-15SA: Asahi Medical Co.,Ltd, Tokyo). This PS dialyzer membrane is reported 
to affect plasma insulin clearance during HD treatment (Abe et al. 2011; Jaber et al. 2000). 
Patients were haemodialysed three times weekly (in fasting state) for a minimum of 4 hours in 
the Christchurch Hospital Intensive Care Unit (ICU).  
Study inclusion from the total of 51 ARF patients required a minimum of 5 hours of patient data 
before dialysis, followed by at least 6 hours of dialysis, and then at least 5 hours after dialysis. 
The clinical details of this cohort are summarized in Table 7.1. The APACHE III diagnosis for 
these patients can be divided into 5 main groups: Sepsis, Cardiovascular, Trauma, Respiratory 
and Diabetes. Full details on SPRINT can be obtained from Chase et al. (2008).  
Table 7.1 SPRINT Cohort baseline variables (N=51). Data are expressed as median [IQR]. (APACHE = 
Acute Physiology and Chronic Health Evaluation). 
 
Median [IQR] 
Age (years) 65 [46-73] 
% Male 76%  
APACHE II score 24 [19-30] 
APACHE III Diagnosis Number of Patients % 
Trauma 9 18 
Cardiovascular 13 25 
Sepsis 20 39 
Respiratory 7 14 
*Diabetes 2 4 
*Patients diagnosed with Type 1 Diabetes Mellitus (T1DM) 
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7.2.2 Identification of SI 
Model-based SI is identified hourly by fitting G measurements with estimated endogenous 
insulin secretion using the ICING-2 (Intensive Control Insulin-Nutrition-Glucose) model (Pretty 
2012). An integral-based method (Hann et al. 2005) and clinical data are used to identify patient-
specific stepwise SI profiles with 1-hour resolution. The model nomenclature is in Equations 7.1–
7.7 and is mathematically defined: 
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Tables 7.2–7.3 indicate the nomenclatures that define ICING-2 model, population parameters 
and kinetics values based on diabetic status and the exogenous input variables in ICING-2 
model. 
Table 7.2 Nomenclature of ICING-2 model. 
Parameters Description  Unit 
G Blood glucose level  mmol.L
-1
 
Q Interstitial insulin level  mU.L
-1
 
I Plasma insulin level  mU.L
-1
 
P1 Stomach glucose content  mmol 
P2 Gut glucose content  mmol 
P Rate of glucose appearance in plasma  mmol.min
-1
 
Uen(G) Endogenous insulin secretion  mU.min
-1
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Table 7.3 Population parameters and kinetics values of ICING-2 model based on diabetic status. 
Parameters Description Value Unit 
EGP Endogenous glucose production 1.16 mmol.min
-1
 
CNS Central nervous system glucose uptake 0.3 mmol.min
-1
 
pG Patient endogenous glucose removal 0.006 min
1
 
SI Insulin sensitivity  L.mU
-1
.min
-1
 
αG Saturation parameter of insulin-mediated glucose 
removal 
0.0154 L.mU
-1
 
VG Plasma glucose distribution volume 13.3 L 
nI Plasma-interstitium insulin diffusion rate 0.006 min
-1
 
nC Receptor-bound insulin degradation 0.006 min
-1
 
nK Renal insulin clearance 0.0542 min
-1
 
nL Hepatic insulin clearance 0.1578 min
-1
 
αI Saturation parameter for hepatic insulin clearance 0.0017 L.mU
-1
 
VI Insulin distribution volume 4.0 L 
xL First pass hepatic clearance 0.67 1 
d1 Rate of glucose transport through the enteral route 
into the bloodstream 
0.0347 min
-1
 
d2 0.0069 min
-1
 
Pmax Maximal gut glucose flux 6.11 mmol.min
-1
 
umin Minimum pancreatic secretion rate 16.7 mU.min
-1
 
umax Maximum pancreatic secretion rate 266.7 mU.min
-1
 
k1 Pancreatic insulin secretion glucose-
sensitivity 
*NGT: 14.9 mU.L. 
mmol
-1
.min
-1
 *T2DM: 4.9 
*T1DM 0.0 
k2 Pancreatic insulin secretion offset *NGT: -49.9 mU.min
-1
 
*T2DM: -27.4 
*T1DM: 16.7 
Uex Intravenous insulin input rate  mU.min
-1
 
D Oral glucose input rate from enteral nutrition  mmol.min
-1
 
PN Intravenous glucose input rate from parenteral 
nutrition 
 mmol.min
-1
 
*Note: NGT=Normal Glucose Tolerance, T1DM=Type 1 Diabetes Mellitus, T2DM=Type 2 Diabetes Mellitus 
Model estimation of endogenous insulin secretion Uen(G) is in the range between 16.7mU.min
-1
 
and 266.7mU.min
-1
 as a function of glycaemic concentration (G) (Pretty 2012). This overall 
metabolic model has been clinically validated with median prediction error less than 4-5% (Lin 
et al. 2011). The model has been used in several clinical glycaemic control trials and insulin 
sensitivity tests (Evans et al. 2011; Fisk et al. 2012; Pretty et al. 2012).  
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7.2.3 Hypothesis 
The model uses fixed values for kidney clearance, nK, and a G dependent model for endogenous 
insulin secretion, Uen. Therefore, the unmodeled changes due to HD or any other effect 
(Jamaludin et al. 2012) are reflected in modeled SI. There are two dialysis transitions, OFF/ON 
and ON/OFF examined in this study. 
 
OFF/ON transition 
The HD PS membrane is known to absorb plasma insulin during dialysis treatment (Abe et al. 
2011), which will lower plasma insulin levels compared to the model estimates. Therefore, it is 
hypothesised that after the OFF/ON transition, SI will decrease given fixed model assumptions 
on Uen and. 
 
ON/OFF transition 
By using the same dialyzer membrane with fixed assumptions on Uen and nK, it is hypothesise 
that SI will increase as the plasma insulin levels recover to higher levels more similar to those 
modeled after HD treatment ends.  
  
Overall, changes in SI due to HD might be caused by either or both of: 
a) Changes in Uen due to HD treatment (Abe et al. 2011; Mak 1995).  
b) Changes in the effective insulin clearance (nK in the model) (Abe et al. 2009; Zhang et al. 
2008).  
 
It is assumed that true SI will remain (largerly) constant over the short transition times for all 
patients. Thus, any larger changes in SI consistent over the cohort and time around a transition 
may be described to the impact of HD therapy. However, tracking changes and the net effect on 
modeled SI after both transitions cannot delineate the separate effects noted above. In particular, 
rising Uen with respect to fix model assumptions leads to an increase in observed SI, while rising 
nK leads to apparent reduction in SI. If SI is decreasing, it means the effect of insulin clearance 
increases outweigh the effect of Uen increases.  
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7.2.4 Data analysis 
Numerical calculations and parameter identification were performed using MATLAB (The 
MathWorks Inc., Natick, MA). The proportional difference in SI (ΔSI) was calculated as: 
     
  ( )    (   )
  ( )    (   )
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Blood glucose changes, ΔG were calculated in a similar manner to assess any changes in 
glycaemia that could affect results. 
This analysis uses a 2-hour moving average to reduce the effect of measurement error, and the 
influence of transient effects. SI profiles are identified over periods starting 3 hours just before 
dialysis commencement until 4-10 hours after dialysis ends. This range ensures full settling of 
patient response after transitions. Patient-specific blood glucose and insulin sensitivity at both 
OFF/ON and ON/OFF dialysis transitions are illustrated distribution and Bland–Altman plots.  
An analysis of p-values that cause ΔSI was performed to investigate the impact of HD therapy on 
nK and Uen. It is assumed that ΔSI is constant and indistinct when p=1 is reached at certain nK and 
Uen parameter values.  
Non-parametric Wilcoxon rank-sum tests were used to assess ∆SI and ∆G over the cohort at each 
transition. This test assesses two samples of independent observations that have distinct median 
values (Wilcoxon et al. 1970). Significant results (p<0.05) show a difference in median values 
for both independent observations. 
7.3 Results and Discussion 
This chapter investigated the impacts of HD treatment on insulin sensitivity, and insulin kinetics 
(based on renal insulin clearance, endogenous insulin secretion and the effective plasma insulin), 
through a clinically validated modeled ΔSI metric at both OFF/ON and ON/OFF dialysis 
transitions. 
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7.3.1 Impacts of HD on SI 
Significant insulin sensitivity changes were observed at the OFF/ON dialysis transition (p=0.02) 
in Figure 7.1 and Table 7.4. This analysis indicates that modeled SI decreased over the initial 4-
hours after HD started and the changes occurred as rapidly as 2 hours. This result implies that 
HD significantly affected plasma insulin levels via changes in renal insulin clearance and/or 
endogenous insulin secretion, compared to baseline model assumptions. 
Figure 7.1 shows ΔSI over 6 hours at the OFF/ON and ON/OFF dialysis transitions. Patients 
diagnosed with pancreatitis, diabetes and other metabolic dysfunctions showed larger variance in 
ΔSI (>-150%). However, the trend at the OFF/ON transition in Figure 7.1(A) and the Bland-
Altman plot of Figure 7.2 is much clearer. These results for both transitions are shown in detail 
in Table 7.4. 
Figure 7.1 Summary of (2 hours before) and 4 hours after dialysis treatment commenced at OFF/ON (A) 
and ON/OFF (B) dialysis transition at t=-2 to t=4 hr (N=51). 
Mak (2000) showed that ARF patients on HD treatment had lower SI during constant 
hyperinsulinemia. Based on this finding, it is suggested that excessive insulin secretion amongst 
ARF patients with reduced insulin-mediated glucose uptake by tissues insulin resistance caused 
constant hyperinsulinemia. As a result, SI decreases 2-3 hours after HD is commenced. However, 
tissue sensitivity to insulin is increased post-dialysis, as waste products (urea and creatinine) 
A 
B 
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were cleared from bloodstream (DeFronzo et al. 1978). Improvement in glucose tolerance is also 
observed and was accounted for by an increase in insulin secretion (48%) post-dialysis 
(DeFronzo et al. 1978). Thus, longer pre- and post-dialysis observations on ΔSI would elucidate 
factors that influence insulin kinetics (insulin clearance or insulin secretion) in critically ill 
patients with ARF. 
Table 7.4 summarises ΔSI over the OFF/ON and ON/OFF transitions for a longer period to 
assess this issue. SI decreased after the OFF/ON dialysis transition until t=2 hours, where it 
settled with median ∆SI=-29% (IQR: [-58, 6] %; p<0.05). There were a comparatively low 
number of confounders, indicating a relatively strong effect is observed. Median ΔSI increased 
by a much more modest and not significant 9% for the ON/OFF transition (Table 7.4), (IQR: [-
15, 28] %; p=0.7) at t=3 hours after the ON/OFF transition. The number of confounders is 
significantly higher for the ON/OFF transition and the p-values indicate that the hypothesized 
effect cannot be confirmed at this transition. G remains effectively constant at both transitions. 
Table 7.4 Results at both OFF/ON and ON/OFF dialysis transitions of 6 hours with inverted SI 
confounders (t=-2 to t=4 hr; N=51). 
*p-values measured by using Wilcoxon rank sum tests, Q1=25% percentile, Q2= 50% percentile, Q3=75% percentile. 
Time 
t (hr) 
OFF/ON (N=51), expect ΔSI < 0 ON/OFF (N=51), expect ΔSI > 0 
Q1 
(%) 
Q2 
(%) 
Q3 
(%) 
p-value ΔSI > 0          % 
(confounders) 
Q1 
(%) 
Q2 
(%) 
Q3 
(%) 
p-value ΔSI < 0            % 
(confounders) 
-2 -7 1 10 0.9 31 61 -13 -4 3 0.7 32 63 
-1 0 0 0 1 0 0 0 0 0 1 0 0 
0 -24 -7 -1 0.3 10 20 -5 1 8 0.9 24 47 
1 -45 -14 -2 0.05 7 14 -7 2 15 0.9 23 45 
2 -58 -29 -6 0.02 5 10 -13 4 26 0.8 21 41 
3 -55 -19 -5 0.03 9 18 -15 9 28 0.7 23 45 
4 -46 -22 -5 0.03 6 12 -15 3 31 0.5 24 47 
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Abe et al. (2007) reported that when using glucose-free dialysate in diabetic patients, plasma 
glucose concentrations were significantly decreased from 2 hour after HD treatment commenced. 
As expected, plasma insulin concentrations were also significantly decreased besides glucose 
concentrations. Thus, SI is decreasing immediately 2 hours after the OFF/ON transition, as 
shown in Figure 7.2(B). In addition, Figure 7.2(A) illustrated that ΔG decreases slightly once HD 
treatment started at t=2 h, showing some added clearance in that region. 
Figure 7.2 Bland-Altman ΔG (A) and ΔSI (B) over the OFF/ON dialysis transition between t=-1 and 2 
(N=51). Median ΔG=8%, Median ΔSI=-29%. 
A substantial change in SI at the OFF/ON dialysis transition indicates a strong and fast process of 
cleaning and clearing toxic substances from blood leading to increased model-based SI due to 
either decreased Uen or increased nK clearance. However, at the ON/OFF dialysis transition, the 
reverse process is a lot slower physiologically. Hence, the model-based SI, after HD in this study 
may be expected to remain largely unchanged, as observed here, even for extended periods after 
HD treatment (in Table 7.5). 
An extended dialysis interval (>10 hours) of ΔSI for both OFF/ON and ON/OFF dialysis 
transition across the N=26 subjects with sufficient data is shown in Table 7.5. SI decreased 
during the OFF/ON dialysis interval until t=8 hours, where it settled to a median reduction of -
25% (IQR: [-10, -51] %; p=0.04). There were only 2 confounders (ΔSI>0) from 26 patients at 
A B 
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t=8 hours. However, while the ON/OFF transition results improved relative to the hypothesized 
effect, the results were still marginally insignificant (p>0.07), so that this effect is clearly smaller 
than hypothesized and cannot be effectively observed in this study. 
Table 7.5 Extended results at both OFF/ON and ON/OFF dialysis transitions of >10 hours with inverted 
SI confounders (t=-2 to t=10 hr; N=26). 
Time 
t (hr) 
OFF/ON (N=26) ON/OFF (N=26) 
Q1 
(%) 
Q2 
(%) 
Q3 
(%) 
p-value ΔSI > 0           % 
(confounders) 
Q1 
(%) 
Q2 
(%) 
Q3 
(%) 
p-value ΔSI < 0           % 
(confounders) 
-2 -4 3 13 0.9 16 62 -15 -6 1 0.7 19 73 
-1 0 0 0 1 0 0 0 0 0 1 0 0 
0 -25 -10 -2 0.4 4 15 -5 3 9 0.8 10 28 
1 -44 -23 -4 0.1 3 12 -7 8 17 0.8 11 42 
2 -56 -30 -6 0.09 2 8 -8 13 32 0.6 9 35 
3 -55 -19 -2 0.09 6 23 -4 18 42 0.3 9 35 
4 -53 -24 -4 0.1 4 15 -13 14 36 0.3 10 28 
5 -53 -29 -8 0.08 4 15 -12 22 44 0.2 10 28 
6 -44 -25 -8 0.1 4 15 -6 23 47 0.1 8 31 
7 -40 -21 -9 0.07 3 12 -5 18 50 0.07 7 27 
8 -51 -25 -10 0.04 2 8 -5 19 39 0.07 7 27 
9 -47 -18 -7 0.04 1 4 -6 22 38 0.07 8 31 
10 -45 -12 -3 0.09 5 19 -4 22 41 0.08 8 31 
*p-values measured by using Wilcoxon rank sum tests, Q1=25% percentile, Q2= 50% percentile, Q3=75% percentile. 
Long-term (4.9 weeks) HD treatment has been shown to normalize insulin sensitivity and result 
in a marked improvement in glucose metabolism (Kobayashi et al. 2000), but this might not 
completely normalize glucose utilization (DeFronzo et al. 1981). It is impossible to delineate the 
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effects that contribute to changes in SI in this study, due to model identifiability issues to separate 
SI and Uen (Docherty et al. 2011). Over longer intervals, as in Table 7.5, inter-patient or intra-
patient variation may further obscure the observation of the effect itself (Pretty et al. 2012).  
Glucose intolerance among critically ill patients with ARF occurs with significant inhibition of 
insulin secretion and a state of peripheral insulin resistance (DeFronzo et al. 1978; Mak 1995) on 
top of insulin resistance from critical illness (Basi et al. 2005). It is also reported that in patients 
with ARF insulin resistance occurred even though glomerular filtration rate (GFR) values were 
still within normal range (Fliser et al. 1998). The effect of insulin resistance can be exacerbated 
by impairment in the role of insulin in maintaining the hepatic glucose balance (DeFronzo et al. 
1981). Specifically, an inability of insulin to stimulate hepatic glucose uptake with decreasing SI 
has been observed in ARF patients (Valera Mora et al. 2003). Thus, understanding the 
pharmacokinetics of insulin during dialysis is clinically important.  
Figure 7.3 Bland-Altman of ΔG (A) and ΔSI (B) over the ON/OFF dialysis transition between t=-1 and 2 
(N=51). Median ΔG=-8%, Median ΔSI =10%. 
The modeled ΔSI at the ON/OFF dialysis transition in this study was insignificant (p>0.05), as in 
Table 7.4-7.5 and in Figure 7.3. It is assumed that acute IV administration of 1,25-
dihydroxyvitamin D3 (1,25(OH)2D3) given to ARF patients during haemodialysis may increase 
insulin secretion and reverse glucose intolerance (Mak 1994). An improvement in glucose 
A B 
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metabolism has been observed in some studies via lower mean glucose during dialysis and more 
rapid disappearance rate of glucose in the immediate post-dialysis period (Alfrey et al. 1967). In 
general, glucose metabolism and renal function are expected to increase gradually after post-
dialysis when toxic substances that are suspected of hindering renal function slowly rebuild their 
levels.  
7.3.2 Impact of HD on nK and Uen 
Plasma insulin is reduced by enhanced insulin clearance due to the PS dialyzer membrane (Abe 
et al. 2011; Jaber et al. 2000) used during HD treatment in this study. It is suggested that the 
most significant reduction in plasma insulin during HD treatment is through absorption of insulin 
across the PS membrane (Abe et al. 2011), where the equilibrium amount of insulin absorbed 
was greatest in positively charged membranes (Zhang et al. 2008). A significant uptake and 
degradation of insulin may occur when renal insulin clearance significantly exceeds GFR (Mak 
2000), as would occur in HD treatment. This enhanced insulin clearance rate and accumulation 
of dialyzable uraemic toxins inhibit insulin degradation. These waste products can be sufficiently 
cleared from bloodstream by HD treatment (Mak 1994).  
Figure 7.4 Renal insulin clearance rate corresponds to p-values that cause ΔSI (↓) of -29% at t=2 hours for 
the OFF/ON transition. 
Figure 7.4 illustrates renal insulin clearance and corresponding to p-values with respect to 
variation in median ΔSI at t=2 hours at OFF/ON transition. This analysis implies that nK is 
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increased by 2.55-fold from the model assumed value of 0.0542 (min
-1
) after HD is commenced. 
Plasma insulin also is suspected to be absorbed through the membrane dialyzer and cleared from 
bloodstream during HD treatment on top of toxins and waste products (urea and creatinine). ΔSI 
is not significant at the OFF/ON transition when p>0.05. Thus, when p-value reaches 1 (p=1), it 
is assumed that the reduction of ΔSI is remained constant and indistinct (-29%). Hence, increased 
modeled nK supported the prior finding that plasma insulin might also be cleared during HD 
treatment via membrane dialyzer absorption or through the dialysate products. 
It is suspected that Uen might also be affected by HD therapy. Thus, Figure 7.5 illustrates Uen and 
corresponding p-values that cause significant decreased ΔSI of -29% at t=2 hours for the 
OFF/ON dialysis transition. Modeled endogenous insulin secretion rate with p = 0.02 clearly 
indicates that Uen also contributes to significant changes in SI during HD.  
Figure 7.5 Endogenous insulin secretion corresponds to p-values that cause ΔSI (↓) of -29% at t=2 hours 
for the OFF/ON transition. 
Plasma insulin levels also depend on endogenous insulin secretion. Physiologically, Uen is 
determined by glycaemic level and the ability of β-cells to respond to blood glucose 
concentrations and changes. However, it was suggested that an increase in endogenous insulin 
secretion may occur in response to HD treatment with PS membrane dialyzer due to reductions 
in plasma insulin (Abe et al. 2007; Jaber et al. 2000; Liljenquist et al. 1978). As the p-value of 
Uen does not reach p=1, it is assumed that variance in Uen could not contribute to the observation 
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ΔSI. In particular, the PS membrane can reduce plasma insulin significantly in HD (Abe et al. 
2007; Abe et al. 2011). Thus, SI would also be expected to decrease with an unmodeled increase 
in Uen during the initial period of HD treatment to maintain G level.  
7.4 Limitations 
Model-based SI is an indication of overall glucose metabolism of critically ill patients and does 
not necessarily reflect the precise cellular physiology of peripheral insulin sensitivity. The larger 
model-based ΔSI at a cohort level found in this study are unlikely to be caused by actual variance 
in true peripheral SI at a cellular level. In particular, there is no apparent stimulus induced by 
haemodialysis to directly affect SI. Thus, ΔSI reflects changes in renal clearance or/and 
endogenous insulin secretion, which result in changes in the modeled SI calculated based on 
fixed assumptions for these values.  
In particular, the ICING-2 model prediction of Uen is made in terms of blood glucose 
concentration in the absence of direct measurement of C-peptide (Pretty 2012). Hence, the effect 
of dialysis on Uen cannot be defined patient-specifically by the model without added data that 
was not available in this study. It is also reported that endogenous insulin secretion is also 
affected by exogenous insulin (Argoud et al. 1987; Liljenquist et al. 1978). As plasma insulin 
levels are suspected to decrease during dialysis, it may also be suspected that endogenous insulin 
secretion would increase, at a cohort level. An increase in the modeled SI over time should be 
observed at the OFF/ON transition, contrary to the observations here, which were much smaller. 
Hence, Uen dependence on blood glucose concentration would confound the observed effect and 
can be discounted as a contributor to the shifts in the modeled SI in this study. Thus, it is most 
likely that effective renal clearance increases during HD and decreases after HD treatment, and is 
the dominant factor. 
Effective Uen identification cannot be undertaken with only glucose data (Docherty 2011; 
Docherty et al. 2009). Thus, a direct measurement of C-peptide should be included in future for 
direct quantification of the effects contributing to the glyceamia of ARF patients. The results of 
this study could be used to confirm these results to power a further study that segregates these 
potential contributing effects. 
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All critically ill patients with ARF in this study were undergoing SPRINT tight glycaemic 
control (TGC), where the minimal changes in G illustrated that SPRINT was successful in 
controlling glycaemia during these transitions. Glycaemic levels and the tightness of this 
protocol also to ensure the analysis results are not biased by variations in glucose levels which 
can affect stress response and thus SI levels. Although there were two diagnosed type 1 diabetes 
patients in this cohort, almost no bias in ΔG was observed. Thus, the confounding factor plays no 
role.  
7.5 Summary 
Overall, this investigation suggests that the most likely contributor to the observed changes in SI 
was the high HD insulin clearance, which was modeled by the renal insulin clearance term. The 
effect of HD on plasma insulin and the mechanism of insulin clearance among critically ill 
patients with ARF were shown in this study to be a contributor in overall effective SI, which 
determines glycaemic concentration. However, further in-depth study must be undertaken to 
measure the specific effects of HD. A prospective cohort and clinical studies with direct insulin 
and C-peptide assays on this cohort may deliver better understanding in insulin kinetics during 
HD treatment. A broad comparison from a different cohort of varied HD duration with mixed 
levels of insulin resistance will also clarify the effects of ΔSI, revealing further details in the 
underlying contributors of specific insulin resistance.   
The distinct change in model-based insulin sensitivity during HD treatment was a significant and 
observable aspect of critically ill patient physiology. The findings were consistent with the 
presence of effects of HD treatment in a majority of ARF patients from other studies. Clinically, 
the effect of the main contributors (nK and Uen) of effective insulin sensitivity changes during HD 
from a baseline model or clinical assumptions suitable for other patients should also be 
considered in glycaemic control. However, the precise pharmaco-kinetics/dynamics driving this 
change remain ambiguous. These results justify larger cohort investigation with specific 
measurement of insulin secretion and renal clearance to differentiate these impacts.   
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Chapter 8. Conclusion  
Diabetes is an epidemic disease that yields catastrophic implications on quality of life, economic 
burden on healthcare systems and the population worldwide. In particular, both the total number 
of affected individuals and the level of associated complications is drastically growing. The 
major complications include polyneuropathy, blindness, kidney failure and limb amputations and 
are beginning to consume a major and increasing portion of worldwide healthcare costs. 
One of the main pathological factors leading to type 2 diabetes is insulin resistance (IR), an 
impaired ability of the body to utilise the available insulin as blood glucose increased. IR is 
evident up to 10 years before type 2 diabetes is discovered. With early diagnosis of T2DM will 
give an opportunity to initiate appropriate treatment and lifestyle interventions to prevent and 
mitigate the effects of this disease before its spread and becomes chronic. Thus, several diagnosis 
assessments with various clinical settings have successfully been proposed in prior studies. 
However, the underlying causes that contribute to the erratic physiological effects in the model-
based assessments are still unclear and ongoing.  
A particular model-based approach allows the observation of metabolic states and defects with a 
minimally invasive test protocol. This minimal test is achieved by compensating for the lack of 
measured data with physiologically accurate models and parameters. A much more accurate and 
complete assessment of the metabolic system is thus possible, than is possible from surrogate 
metrics. A short clinical test has specifically developed by integrating practical clinical aspects 
and modelling techniques to further investigate the dynamics of the metabolic effects and its 
causes especially in IGT/T2DM. 
Importantly, to validate the model-based SI tests, parameter identification of PK-PD models 
using pilot DISST responses with iterative integral method (IIM) allows an independent 
examination of the model roles of αG and nI for describing true physiological glucose-insulin 
pharmacodynamics and pharmacokinetics. Increasing the number of identified participant-
specific parameters did not necessarily improve model accuracy, as plasma insulin model fitting 
error was quite high compared to fitting error in plasma glucose. Very low values for αG and nI 
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are found to produce the most intra-patient variability in SI. A model accounting for insulin 
receptor saturation of αG=0.05 with nI=0.055 enhanced the repeatability in SI. These SI values 
derived using these αG and nI parameter values have correlation of R=0.85 with gold-standard 
EIC. This set of parameter values produced low median SI variation amongst all subjects where 
the inter-quartile range was also tight with median 12% [IQR: 11, 14]%. A cohort of patients 
with mixed levels of insulin resistance will also further validate the accuracy of the model-based 
SI and may provide a better understanding of the contributing factors of insulin resistance. A 
unique participant-specific identification of αG and nI might suggest the best possible 
repeatability of SI. This might also increase model fitting accuracy of plasma insulin and 
interstitial insulin. 
An analysis using the ICING model shows the distinct existence of an incretin effect as an 
observable aspect of critically ill patient physiology. The observation of this metabolic effect was 
based on ΔSI at ON/OFF and OFF/ON enteral feeding transitions. The most significant 
observable incretin effect of decreased in ΔSI=-36 was found at t=4 hours after (ON/OFF) EN 
feeding was stopped. The findings were consistent with the presence of an EN-related incretin 
effect in a majority of critically ill patients. Clinically, the existence of this effect at EN nutrition 
transitions should also be considered in the management of glycaemia and could influence 
design of this therapy. While the results observed valid surrogates of the incretin effects, a 
prospective study with direct measurement and powered by these results may be required to 
confirm the outcomes directly. 
Presumably, the incretin effects that occur during OGTT potentially adds] significant value to the 
DISST model via tracking and evaluating    and   controller gains of Uen control model 
amongst normal subject who underwent both DISST and OGTT challenges. However, 
insignificant results were observed which indicated that incretin effects were unobservable in 
OGTT response as 
  
  
 OGTT < 
  
  
 DISST. The Uen control model and methods proposed here 
enable one to obtain a specific observation on both β-cell function and insulin kinetics in a single 
approach and delivered a good compromise between model simplicity and accuracy. Hence 
measurements of plasma C-peptide concentration and the use of the independent glucose-insulin 
PK-PD models for glucose-insulin regulatory mechanism could provide unique insight into the 
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pathogenesis of T2DM and the metabolic syndromes. Finally, the proposed Uen control model of 
insulin secretion and kinetics will provide the ability to precisely define the pancreatic β-cell 
function in relation to insulin sensitivity. 
An analysis of the impact of HD therapy on insulin sensitivity and insulin kinetics was also 
performed. The investigation suggested that the most likely contributor to the observed changes 
in SI was the HD insulin clearance. The effect of HD on plasma insulin and the mechanism of 
insulin clearance among critically ill patients with ARF were shown in this analysis to be a 
contributor in the overall effective SI, which physiologically illustrate the glucose-insulin 
metabolic system during HD therapy. 
The distinct change in the model-based insulin sensitivity during HD treatment was a significant 
and observable aspect of critically ill patient physiology. The findings were consistent with the 
presence of effects of HD treatment in a majority of ARF patients from other studies. Clinically, 
the effect of the main contributors (nK and Uen) of effective insulin sensitivity changes during HD 
from a baseline model or clinical assumptions suitable for other patients should also be 
considered in glycaemic control. However, the precise pharmaco-kinetics/dynamics driving this 
change remain ambiguous. These results justify larger cohort investigation with specific 
measurement of insulin secretion and renal clearance to differentiate these impacts. Further in-
depth study must be undertaken to measure the specific effects of HD. A prospective cohort and 
clinical studies with direct insulin and C-peptide assays on this cohort may deliver better 
understanding in insulin kinetics during HD treatment. A broad comparison from a different 
cohort of varied HD duration with mixed levels of insulin resistance will also clarify the effects 
of ΔSI, revealing further details in the underlying contributors of specific insulin resistance.   
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Chapter 9. Future Work 
  
The analyses presented in this thesis addressed several limitations in assessing and integrating 
the dynamics and metabolic effects of PK-PD models in wider clinical and research settings. 
Further improvements in the clinically validated PK-PD models hopefully can provide better 
understanding of these underlying effects that cause variability within physiological range of PK-
PD models. 
9.1 Incretin measurements and modelling 
The relative insulin secretion across PN/EN feeds must be directly measured to validate the 
observation of incretin effects in critically ill patients. The analysis in Chapter 5 only used EN 
nutrition without gastrointestinal hormones (GLP-1 and GIP) measurements. Thus, an ideal 
study design for the observation of incretin either in critically ill patients would also use PN 
feeding in a cross-over format.  
A further study with varying insulin resistant levels cohort could also incorporate direct 
measurement of the gastrointestinal hormones. This approach would allow direct incorporation 
and identification of additional incretin hormone-related model parameters, as well as direct 
measurement of the effect without relying on PN measurements. Also, the variability of the 
incretin effects can be observed with a larger and varied insulin resistant cohort. Thus, modeling 
GLP-1/GIP with respect to insulin secretion and β-cell glucose sensitivity could validate the 
assumptions this evaluation of the incretin effect. This proposed approach will validate the prior 
finding as it will allow simultaneous estimation of both β-cell glucose sensitivity and the ability 
of GLP-1 and GIP to enhance insulin secretion. 
9.2 Stomach and gut model/meal stimulator 
An accurate model of the glucose-insulin system in the postprandial state is required for studying 
the pathophysiology of the diabetes. In particular, such a model would be required for design and 
evaluating the glucose sensor/control algorithms, decision support systems for treating diabetes 
and to investigate the metabolic effects in the postprandial state. The importance of developing a 
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stomach and gut model (meal simulator) is to allow model-based interpretation of the oral 
glucose ingestion used in everyday meals. However, the oral route is more difficult to model 
than the intravenous route because the model has also to describe the glucose ingestion and 
absorption processes. A few oral simulation models are available (Andreassen et al. 1994; 
Lehmann and Deutsch 1992). The major limitations of these models are that both have been only 
validated on plasma concentration data not in clinical setting.  
A stomach and gut model should describe the physiological events that occur after a meal by 
uniquely integrating the validated stomach and gut model with glucose-insulin (PK-PD) models. 
This would direct the investigation of the metabolic effects (i.e. incretin effects) in the 
postprandial state that is assumed to contribute to the overall insulin secretion by β-cells in 
pancreas. Thus, a parameter identification study on the stomach and gut model that enhances 
insulin secretion via incretin effects should be undertaken. 
9.3 Endogenous insulin secretion model 
An endogenous insulin secretion control model that is a function of glucose concentrations has 
been proposed to segregate the incretin effects after oral glucose ingestion. Due to limited 
glucose data and unavailability of C-peptide measurement, the proposed model failed to 
segregate this metabolic effect between IV and oral glucose inputs.  Although this Uen control 
model is well-functioned in DISST responses, the wide range of physiological disorders of IR 
individuals obscure the true dynamics and metabolic effects that occurred. A refined study of β-
cell function that affects insulin secretion would combine higher resolution data to accurately 
define the secretion profile. Also, the blood glucose assays coinciding with the other samples (C-
peptide and insulin) would provide a better basis for a model as a function of both G and C-
peptide with its time derivatives.   
9.4 Reliability and high frequency of clinical data measurements 
It is important to measure high frequency of glucose and insulin data especially after IV/oral 
glucose input. The high data density may enable other model parameters to be identified, which 
portray the true physiological effects or at least, characterised in a more participant-specific 
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manner.  Thus, a further study using current glucose meter devices with continuous glucose 
monitoring (CGM) sensor technology could potentially increase the data resolution. Current 
CGM technology in glucose meters consists useful features:  
 Multi-test systems: Some systems use a cartridge or a disc containing multiple test strips. 
This has the advantage that the user does not have to load individual strips each time, 
which is convenient and can enable prompt testing.  
 No coding systems: Older systems required coding of the strips to the meter. This carried 
a risk of miscoding, which can lead to inaccurate results/noise. Two approaches have 
resulted in systems that without coding. Some systems are auto-coded, where technology 
is used to code each strip to the glucose meter. And some are manufactured to a single 
code, thereby avoiding the risk of miscoding.  
 The downloadable meters. Almost recent systems come with software that allows the 
user to download meter results to a computer. This information can then be used, together 
with clinicians‘ guidance to enhance and improve diabetes management. The meters 
usually require a connection cable, unless the meters are designed to work wirelessly with 
an insulin pump, or are designed to plug directly into the computer.  
Overall, continuous monitoring allows examination on the blood glucose concentration response 
to insulin, physical exercise, food and other factors. The additional data can be useful for setting 
correct insulin dosing ratios for food intake and correction of hyperglycemia. Monitoring during 
periods when blood glucose concentrations are not typically checked (e.g. overnight) can help to 
identify problems in insulin dosing (such as basal levels for insulin pump users or long-acting 
insulin levels for patients taking injections). Monitors may also be equipped with alarms to alert 
patients of hyperglycemia or hypoglycemia so that a patient can take corrective action(s) (after 
fingerstick testing, if necessary) even in cases where they do not feel symptoms of either 
condition. While the technology has its limitations, studies have demonstrated that patients with 
continuous sensors experience less hyperglycaemia (Bode et al. 2004; Boland et al. 1999; 
Klonoff 2005; Pretty et al. 2010). 
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